

# CITATION REPORT

List of articles citing

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

DOI: 10.1097/01.md.0000091181.93122.55  
Medicine (United States), 2003, 82, 299-308.

**Source:** <https://exaly.com/paper-pdf/35692622/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1000	Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. <b>2004</b> , 351, 260-7		168
999	Large scale evidence and replication: insights from rheumatology and beyond. <b>2005</b> , 64, 345-6		5
998	Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. <b>2004</b> , 3, 423-53		130
997	Perspectives on the changing face of lupus mortality. <b>2004</b> , 3, 415-7		5
996	Lupus mortality in Japan. <b>2004</b> , 3, 421-2		3
995	[Therapeutical perspectives in systemic lupus erythematosus]. <b>2004</b> , 123, 540-2		3
994	Management of the neurological manifestations of APS--what do the trials tell us?. <b>2004</b> , 114, 489-99		36
993	[Antiphospholipids, systemic lupus, and atherosclerosis: clinical features]. <b>2004</b> , 25 Suppl 1, S12-3		
992	The Epidemiology of Lupus Erythematosus. <b>2005</b> , 33-44		1
991	Rein et lupus : donn^ es r^ centes. <b>2005</b> , 72, 162-167		0
990	Principes g^ h^ faux des traitements du lupus ^ tyth^ mateux syst^ mique et mesures pr^ ventives. <b>2005</b> , 72, 537-545		
989	[Cardiovascular monitoring of patients with systemic lupus erythematosus]. <b>2005</b> , 64, 564-75		2
988	Can survival of systemic lupus erythematosus be further improved?. <b>2005</b> , 8, 159-164		1
987	Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. <b>2005</b> , 68, 813-7		109
986	The role of immune ablation and stem cell transplantation in severe SLE. <b>2005</b> , 19, 839-58		16
985	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. <b>2005</b> , 52, 1473-80		261
984	Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. <b>2005</b> , 52, 2774-82		164

983	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. <b>2005</b> , 53, 609-12		61
982	Antiphospholipid antibodies in young adults with stroke. <b>2005</b> , 20, 105-12		44
981	Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. <i>Rheumatology</i> , <b>2005</b> , 44, 756-61	3.9	110
980	Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. <i>Rheumatology</i> , <b>2005</b> , 44, 1317-21	3.9	38
979	Pneumococcal sepsis in patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2005</b> , 14, 903-6	2.6	35
978	Serositis related to systemic lupus erythematosus: prevalence and outcome. <i>Lupus</i> , <b>2005</b> , 14, 822-6	2.6	93
977	High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. <i>Lupus</i> , <b>2005</b> , 14, 529-33	2.6	53
976	Lupus eritematoso sistémico. <b>2005</b> , 9, 1942-1952		
975	[Atheroma and auto-immunity: 50th congress of the National French Society of Internal Medicine]. <b>2005</b> , 34, 57-61		
974	Osteoporosis in systemic lupus erythematosus mechanisms. <b>2005</b> , 31, 363-85, viii		28
973	Systemic lupus erythematosus. <b>2005</b> , 52, 443-67, vi		67
972	Lupus eritematoso sistémico. <b>2005</b> , 38, 1-24		
971	Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients. <i>Lupus</i> , <b>2005</b> , 14, 938-46	2.6	91
970	Infections and SLE. <b>2005</b> , 38, 473-85		211
969	Lupus érythémateux systémique. <b>2005</b> , 2, 1-32		5
968	Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. <i>Rheumatology</i> , <b>2006</b> , 45, 53-60	3.9	64
967	Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. <b>2006</b> , 35, 85-95		39
966	[Experience with rituximab in the treatment of systemic erythematosus lupus]. <i>Reumatologia Clínica</i> , <b>2006</b> , 2, 23-30	0.9	3

965	Systemic lupus erythematosus. <b>2006</b> , 1, 6	120
964	Long-term prognosis and causes of death in systemic lupus erythematosus. <b>2006</b> , 119, 700-6	215
963	Cerebral Ischemia in Antiphospholipid Syndrome. <b>2006</b> , 53-67	
962	Antiphospholipid (Hughes) Syndrome: An Overview. <b>2006</b> , 9-21	4
961	Lupus ^ lyth ^ mateux syst ^ mique. <b>2006</b> , 1, 1-21	
960	An overview of clinical manifestations and survival of systemic lupus erythematosus patients in Asia. <b>2006</b> , 9, 336-341	11
959	[Systemic lupus erythematosus--activity and outcome]. <b>2006</b> , 65, 103-6, 108-9	2
958	Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center. <b>2007</b> , 27, 243-9	27
957	Update on rheumatologic mimics of fibromyalgia. <b>2006</b> , 10, 327-32	5
956	Fatal multidrug-resistant <i>Acinetobacter baumannii</i> sepsis in a patient with travel history and recent onset of systemic lupus erythematosus: a case report. <b>2006</b> , 209, 581-3	3
955	Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". <b>2006</b> , 5, 180-6	99
954	European Working Party on Systemic Lupus Erythematosus: a 15-year report. <b>2006</b> , 5, 549-53	19
953	Fever and musculoskeletal symptoms in an adult: differential diagnosis and management. <b>2006</b> , 20, 641-51	3
952	Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. <b>2006</b> , 55, 74-80	63
951	Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus. <b>2006</b> , 55, 427-33	39
950	Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. <b>2006</b> , 55, 799-806	85
949	A frayed knot. <b>2006</b> , 1, 361-6	
948	Estimation of glomerular filtration rate in patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2006</b> , 15, 276-81	2.6 13

947	Epidemiology of systemic lupus erythematosus at the change of the millennium: lessons from the Euro-Lupus and the LUMINA projects. <i>Lupus</i> , <b>2006</b> , 15, 1-2	2.6	9
946	Lack of flow-mediated dilation and enhanced angiotensin II-induced constriction in skeletal muscle arterioles of lupus-prone autoimmune mice. <i>Lupus</i> , <b>2006</b> , 15, 326-34	2.6	11
945	Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. <i>Lupus</i> , <b>2006</b> , 15, 881-5 <sup>6</sup>	2.6	33
944	The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus. <b>2006</b> , 2, 377-85		11
943	Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2006</b> , 15, 577-83	2.6	279
942	Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2007</b> , 16, 505-8	2.6	41
941	Management of systemic lupus erythematosus in Chinese patients. <b>2007</b> , 3, 925-35		4
940	Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. <i>Lupus</i> , <b>2007</b> , 16, 997-1000	2.6	39
939	LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. <b>2007</b> , 8, 873-9		12
938	Thirty years of cyclophosphamide: assessing the evidence. <i>Lupus</i> , <b>2007</b> , 16, 212-6	2.6	23
937	African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). <b>2007</b> , 66, 618-22		36
936	Current management of lupus nephritis: popular misconceptions. <i>Lupus</i> , <b>2007</b> , 16, 217-20	2.6	8
935	Future prospects in the treatment of lupus nephritis: proliferative lupus nephritis. <b>2007</b> , 2, 297-303		0
934	Infection in systemic lupus erythematosus. <b>2007</b> , 37, 792-5		10
933	Dilemma of drug-eluting stent implantation in a patient with systemic lupus erythematosus. <b>2007</b> , 114, e107-8		3
932	[What to do to improve the survival of patients with systemic lupus erythematosus?]. <b>2007</b> , 128, 95-6		0
931	Systemic lupus erythematosus. <b>2007</b> , 33, 471-98, vi		23
930	Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. <i>Lupus</i> , <b>2007</b> , 16, 309-17	2.6	162

929	Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors. <b>2007</b> , 36, 198-205	26
928	Systemic lupus erythematosus: an international perspective on healthcare costs and health status outcomes. <b>2007</b> , 2, 399-402	1
927	[New concepts in the treatment of lupic nephropathy]. <b>2007</b> , 207, 570-2	
926	Systemic Lupus Erythematosus. <b>2007</b> , 681-685	
925	Autoimmune and Inflammatory Disorders. <b>2007</b> , 1155-1184	
924	Nocardia sepsis in a multigravida with systemic lupus erythematosus and autoimmune hepatitis. <b>2007</b> , 35, 601-4	3
923	Traitements actuels des néphropathies lupiques. <b>2007</b> , 74, 759-764	0
922	Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. <b>2007</b> , 61, 1561-8	16
921	Advances in lupus and Sjögren's syndrome: a tribute to Josep Font. <b>2007</b> , 1108, 51-63	
920	[Modern therapy for systemic lupus erythematosus]. <b>2007</b> , 66, 662-6, 668-71	4
919	Skin damage occurs early in systemic lupus erythematosus and independently of disease duration in Brazilian patients. <b>2007</b> , 27, 483-7	14
918	Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. <b>2007</b> , 27, 735-41	43
917	Clinical outcomes of childhood lupus nephritis: a single center's experience. <b>2007</b> , 22, 222-31	64
916	Neurologic manifestations of the antiphospholipid syndrome. <b>2007</b> , 9, 109-15	29
915	Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. <b>2008</b> , 10, 67-73	22
914	Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. <b>2008</b> , 27, 345-51	29
913	Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. <b>2008</b> , 27, 1377-85	58
912	A national study of the complications of lupus in pregnancy. <b>2008</b> , 199, 127.e1-6	321

911 Current therapy of lupus nephritis. Which is the best option?. **2008**, 208, 138-41

910 Treatment of Lupus Nephritis. **2008**, 4, 140-151

909 Tratamiento de inducci3n en la nefritis l3tica tipo IV. **2008**, 9, 105-110

908 Factores asociados a la mortalidad del lupus eritematoso sist3mico. **2008**, 9, 219-234

7

907 Current treatment of lupus nephritis. *Lupus*, **2008**, 17, 426-30

2.6 64

906 Long-term follow-up after percutaneous coronary intervention in patients with systemic lupus erythematosus. **2008**, 126, 430-2

4

905 Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS -SLE (depression). **2008**, 31, 393-8

59

904 [Infectious complications in systemic lupus erythematosus: a series of 146 patients]. **2008**, 29, 626-31

8

903 [Treatment of proliferative glomerulonephritis of systemic lupus erythematosus. Recent development and current recommendations]. **2008**, 29, 710-7

3

902 [Treatment of lupus nephritis]. *Reumatolog3a Cl3nica*, **2008**, 4, 140-51

0.9

901 Cytokines and their receptors as biomarkers of systemic lupus erythematosus. **2008**, 8, 189-98

34

900 Poliartralgias, fiebre y rash cut3neo como manifestaci3n de lupus eritematoso sist3mico en una mujer adolescente. **2008**, 34, 411-414

899 Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. *Lupus*, **2008**, 17, 1096-102

2.6 56

898 Long-term outcome of Chinese patients with membranous lupus nephropathy. *Lupus*, **2008**, 17, 56-61

2.6 38

897 Pulmonary and thrombotic manifestations of systemic lupus erythematosus. **2008**, 133, 271-80

81

896 Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. *Lupus*, **2008**, 17, 596-604

2.6 94

895 Lupus and the central nervous system. *Lupus*, **2008**, 17, 376-9

2.6 17

894 Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study. *Lupus*, **2008**, 17, 1042-8

2.6 34

893	NEUROLOGIC MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID ANTIBODY SYNDROME. <b>2008</b> , 14, 94-119		3
892	Lupus Nephritis. <b>2008</b> , 329-342		
891	Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. <b>2008</b> , 144, 1341-9		40
890	Coronary Artery Calcification Measured by Multi-Detector Computed Tomography in Systemic Sclerosis. <b>2009</b> , 16, 181		
889	Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. <i>Lupus</i> , <b>2009</b> , 18, 1053-60	2.6	78
888	European Working Party on systemic lupus erythematosus and European Forum on Antiphospholipid Antibodies: two networks promoting European research on autoimmunity. <i>Lupus</i> , <b>2009</b> , 18, 863-8	2.6	9
887	Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. <b>2009</b> , 94, 1671-7		34
886	Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. <i>Rheumatology</i> , <b>2009</b> , 48, 1451-4	3.9	144
885	Prognostically distinct clinical patterns of systemic lupus erythematosus identified by cluster analysis. <i>Lupus</i> , <b>2009</b> , 18, 1267-75	2.6	38
884	Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort. <i>Lupus</i> , <b>2009</b> , 18, 958-65	2.6	39
883	Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. <b>2009</b> , 61, 822-9		210
882	Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. <b>2009</b> , 61, 830-9		175
881	Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. <b>2009</b> , 28, 65-70		25
880	Osteoporosis in children: pediatric and pediatric rheumatology perspective: a review. <b>2009</b> , 7, 16		27
879	The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. <i>Lupus</i> , <b>2009</b> , 18, 869-74		118
878	Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. <i>Lupus</i> , <b>2009</b> , 18, 848-55	2.6	49
877	[Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases]. <b>2009</b> , 38, 243-50		1
876	[Vaccination in patients with systemic diseases]. <b>2009</b> , 38, 235-42		1



875	Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. <i>Lupus</i> , 2009, 18, 767-76	2.6	237
874	The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. <i>Lupus</i> , 2009, 18, 807-12	2.6	48
873	Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. <i>Lupus</i> , 2009, 18, 465-73	2.6	71
872	Thrombosis in systemic lupus erythematosus: risk and protection. 2009, 7, 1541-9		23
871	How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?. 2009, 11, 129		21
870	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. 2009, 11, R154		88
869	Predictors of major infections in systemic lupus erythematosus. 2009, 11, R109		222
868	[High cardiovascular complications in systemic lupus erythematosus: physiopathology and risk management]. 2009, 5, 595-602		1
867	Therapeutic approaches to secondary immune thrombocytopenic purpura. 2009, 46, S44-58		11
866	Protocolo diagn <sup>o</sup> stico de fiebre en un paciente con lupus eritematoso sist <sup>o</sup> mico. 2009, 10, 2163-2165		
865	Thrombophilic patterns of coagulation factors in lupus. <i>Lupus</i> , 2009, 18, 400-6	2.6	14
864	TNF inhibition in SLE: where do we stand?. <i>Lupus</i> , 2009, 18, 5-8	2.6	13
863	Actualidad en el tratamiento de la nefritis l <sup>o</sup> gica proliferativa. <i>Revista Colombiana De Reumatolog<sup>a</sup></i> , 2009, 16, 76-96	0.2	
862	Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. 2009, 114, 341-353		51
861	Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. 2009, 36, 68-75		41
860	Incidence of symptomatic vertebral fracture with high-dose glucocorticoid treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006. 2009, 56, 591-9		9
859	Lupus nephritis. 2009, 337, 451-60		23
858	Incidence of cancer among female patients with systemic lupus erythematosus in Korea. 2010, 29, 381-8		44

857	Systemic lupus erythematosus. <b>2010</b> , 24, 841-55		77
856	Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid. <b>2010</b> , 7, 218-29		13
855	Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. <b>2010</b> , 99, 967-74		27
854	Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. <b>2010</b> , 62, 386-92		29
853	Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. <b>2010</b> , 62, 266-73		52
852	Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. <b>2010</b> , 62, 873-80		131
851	Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. <b>2010</b> , 62, 993-1001		34
850	Development and initial validation of a self-assessed lupus organ damage instrument. <b>2010</b> , 62, 559-68		33
849	Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. <b>2010</b> , 62, 2458-66		280
848	Significantly higher percentage of circulating CD27(high) plasma cells in systemic lupus erythematosus patients with infection than with disease flare-up. <b>2010</b> , 51, 924-31		13
847	Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan. <b>2010</b> , 184, 2175-82		20
846	Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. <i>Lupus</i> , <b>2010</b> , 19, 231-8	2.6	14
845	The need to revisit the nosology of cutaneous lupus erythematosus: the current terminology and morphologic classification of cutaneous LE: difficult, incomplete and not always applicable. <i>Lupus</i> , <b>2010</b> , 19, 1047-9	2.6	25
844	Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <b>2010</b> , 69, 2083-9		335
843	Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. <b>2010</b> , 37, 1467-72		33
842	Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus. <b>2010</b> , 37, 1158-63		33
841	Multiple septic bursitis and spontaneous Achilles tendon tear in systemic lupus erythematosus. <b>2010</b> , 37, 2438-40		5
840	Principles in Management of Systemic Lupus Erythematosus. <b>2010</b> , 83-90		

839	Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2010</b> , 19, 949-56	2.6	108
838	ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. <b>2010</b> , 69, 1329-32		60
837	A new role for antimalarials in systemic lupus erythematosus treatment. <b>2010</b> , 5, 299-312		1
836	Glomerular disease: why is there a dearth of high quality clinical trials?. <b>2010</b> , 78, 337-42		27
835	Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. <b>2010</b> , 9, 447-57		6
834	Antiphospholipid syndrome and the brain in pediatric and adult patients. <i>Lupus</i> , <b>2010</b> , 19, 406-11	2.6	45
833	Ocena przebiegu oraz skuteczności stosowanego leczenia toczniowego zapalenia nerek u dzieci. <b>2010</b> , 85, 328-335		
832	Biological therapy for lupus nephritis-tribulations and trials. <b>2010</b> , 6, 547-52		11
831	Neurologic manifestations of systemic lupus erythematosus in children and adults. <b>2010</b> , 28, 61-73		153
830	[Damage in cuban patients with systemic lupus erythematosus. Relation with disease features]. <i>Reumatologia Clínica</i> , <b>2010</b> , 6, 11-5	0.9	9
829	[Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus]. <i>Reumatologia Clínica</i> , <b>2010</b> , 6, 82-5	0.9	2
828	[Use of rituximab in the treatment of lupus patients. The LESIMAB database]. <i>Reumatologia Clínica</i> , <b>2010</b> , 6 Suppl 2, 28-33	0.9	5
827	Damage in Cuban patients with systemic lupus erythematosus. Relation with disease features. <b>2010</b> , 6, 11-15		
826	Treatment with rituximab for thrombocytopenia due to systemic lupus erythematosus. <b>2010</b> , 6, 82-85		
825	Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. <b>2010</b> , 36, 53-80, vii-viii		176
824	Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. <i>Lupus</i> , <b>2010</b> , 19, 1050-70	2.6	127
823	The future of lupus therapy modulating autoantigen recognition. <i>Lupus</i> , <b>2010</b> , 19, 1474-81	2.6	1
822	Health-Related Quality of Life in Adults with Systemic Lupus Erythematosus. <b>2010</b> , 3261-3279		3

821	Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. <b>2010</b> , 20, 168-177		5
820	Diagnosis and management of juvenile-onset SLE. <b>2011</b> , 21, 539-545		2
819	Toward better treatment for lupus nephritis. <b>2011</b> , 365, 1929-30		7
818	Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. <i>Lupus</i> , <b>2011</b> , 20, 1219-26	2.6	37
817	Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. <i>Lupus</i> , <b>2011</b> , 20, 1027-34	2.6	38
816	Glucocorticoid-induced diabetes mellitus is a risk for vertebral fracture during glucocorticoid treatment. <b>2011</b> , 93, e18-20		5
815	Quels auto-anticorps pour le diagnostic et le suivi de la n <sup>e</sup> phropathie lupique ?. <b>2011</b> , 26, 113-117		0
814	Pleural and pulmonary involvement in systemic lupus erythematosus. <b>2011</b> , 40, e19-29		37
813	[Flu vaccine and auto-immune and/or inflammatory diseases]. <b>2011</b> , 40, 248-52		1
812	Infections in rheumatology practice: an experience from NIMS, Hyderabad. <b>2011</b> , 6, 25-30		3
811	Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , <b>2011</b> , 14, 276-81	2.3	1
810	Survival rate among Thai systemic lupus erythematosus patients in the era of aggressive treatment. <i>International Journal of Rheumatic Diseases</i> , <b>2011</b> , 14, 353-60	2.3	5
809	Glomerulopat <sup>as</sup> secundarias a enfermedades sist <sup>emicas</sup> . <b>2011</b> , 10, 5560-5580		
808	Mujer joven con astenia, rash malar y deterioro de la funci <sup>on</sup> renal. <b>2011</b> , 10, 5594.e1-5594.e3		
807	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <b>2011</b> , 377, 721-31		1206
806	Two Cases of Necrotizing Fasciitis in Patients with SLE. <b>2011</b> , 18, 132		
805	Mast Cells in Kidney Regeneration. <b>2011</b> , 103-123		
804	Systemic Lupus Erythematosus. <b>2011</b> , 1083-1108		

803 EMERGENCY MANAGEMENT OF CONNECTIVE TISSUE DISORDERS AND THEIR COMPLICATIONS. 245-255

802 Clearing the complexity: immune complexes and their treatment in lupus nephritis. **2011**, 4, 17-28 15

801 SLE in Children. **2011**, 573-597

800 Epidemiology of Systemic Lupus Erythematosus. **2011**, 673-696 9

799 SYSTEMIC LUPUS ERYTHEMATOSUS. **2011**, 315-343 20

798 Infections in the lupus patient: perspectives on prevention. **2011**, 23, 358-65 53

797 Neuropsychiatric systemic lupus erythematosus. **2011**, 9, 449-57 116

796 Lethal manifestations of systemic lupus erythematosus in a forensic context. **2011**, 56, 423-8 19

795 Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice. *American Journal of Kidney Diseases*, **2011**, 57, 498-507 7.4 9

794 Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. **2011**, 10, 341-52 106

793 Epidemiology and management of refractory lupus nephritis. **2011**, 10, 655-63 44

792 [Changes in mortality and morbidity in systemic lupus erythematosus]. **2011**, 70, 480-5 11

791 Psychiatric disorders in patients with systemic lupus erythematosus: association of anxiety disorder with shorter disease duration. **2011**, 31, 1387-91 34

790 [Managing comorbidities of inflammatory rheumatic diseases]. **2011**, 52, 688-96 0

789 Rituximab therapy in lupus nephritis: current clinical evidence. **2011**, 40, 159-69 31

788 The persistent challenge of lupus nephritis. **2011**, 40, 135-7 8

787 Lupus nephritis in Colombians: contrasts and comparisons with other populations. **2011**, 40, 199-207 24

786 Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. **2011**, 9, 1 311

785	Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. <b>2011</b> , 63, 865-74		185
784	Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. <b>2011</b> , 63, 1681-8		157
783	The United States to Africa lupus prevalence gradient revisited. <i>Lupus</i> , <b>2011</b> , 20, 1095-103	2.6	34
782	Epidemiology and clinical outcomes of bloodstream infections among lupus patients. <i>Lupus</i> , <b>2011</b> , 20, 965-71	2.6	21
781	Antiphospholipid antibodies and the brain: a consensus report. <i>Lupus</i> , <b>2011</b> , 20, 153-7	2.6	32
780	Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives. <i>Lupus</i> , <b>2011</b> , 20, 537-43	2.6	18
779	Neutropenia and the risk of infections in ambulatory patients with systemic lupus erythematosus: a three-year prospective study cohort. <i>Lupus</i> , <b>2011</b> , 20, 998-1000	2.6	5
778	The causes of death in Korean patients with systemic lupus erythematosus over 11 years. <i>Lupus</i> , <b>2011</b> , 20, 989-97	2.6	24
777	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <b>2011</b> , 70, 2071-4		47
776	Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. <i>Lupus</i> , <b>2011</b> , 20, 28-34	2.6	67
775	Predictors of longterm mortality in patients with and without systemic lupus erythematosus on maintenance dialysis: a comparative study. <b>2011</b> , 38, 2390-4		17
774	Urinary monocyte chemotactic protein-1 and transforming growth factor- $\beta$ in systemic lupus erythematosus. <i>Indian Journal of Nephrology</i> , <b>2012</b> , 22, 5-12	0.8	15
773	Another consequence of severe lupus: invasive fungal disease. <b>2012</b> , 39, 1772-4		3
772	Risks, subtypes, and hospitalization costs of stroke among patients with systemic lupus erythematosus: a retrospective cohort study in Taiwan. <b>2012</b> , 39, 1611-8		19
771	Systemic lupus erythematosus: disease manifestations in patients from Central Punjab (Pakistan). <b>2012</b> , 7, 607-614		0
770	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. <b>2012</b> , 27, 1924-30		33
769	Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. <i>Lupus</i> , <b>2012</b> , 21, 1063-76	2.6	77
768	Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. <i>Lupus</i> , <b>2012</b> , 21, 1025-35	2.6	42

767	Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects. <i>Lupus</i> , <b>2012</b> , 21, 596-603	2.6	33
766	Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. <b>2012</b> , 39, 2111-7		32
765	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. <b>2012</b> , 47, 770-90		194
764	NFKB1 -94 insertion/deletion ATG polymorphism contributes to risk of systemic lupus erythematosus. <b>2012</b> , 31, 611-5		23
763	Thrombosis in systemic lupus erythematosus: a review article. <b>2012</b> , 2012, 428269		31
762	Neuropsychiatric features of a cohort of patients with systemic lupus erythematosus. <b>2012</b> , 2012, 989218		10
761	Role of hsp90 in systemic lupus erythematosus and its clinical relevance. <b>2012</b> , 2012, 728605		29
760	Lupus nephritis: an overview of recent findings. <b>2012</b> , 2012, 849684		64
759	Risk factors for renal failure in patients with lupus nephritis: data from the spanish registry of glomerulonephritis. <b>2012</b> , 2, 269-77		14
758	Treatment of proliferative and membranous lupus nephritis: review of key clinical trials. <b>2012</b> , 343, 86-90		6
757	Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. <b>2012</b> , 379, 244-9		243
756	Survival analysis of late-onset systemic lupus erythematosus: a cohort study in China. <b>2012</b> , 31, 1683-9		20
755	Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. <b>2012</b> , 39, 1819-28		82
754	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <b>2012</b> , 64, 797-808		863
753	Cognitive and emotional abnormalities in systemic lupus erythematosus: evidence for amygdala dysfunction. <b>2012</b> , 22, 252-70		20
752	Venous thromboembolic disease in systemic autoimmune diseases: an association to keep in mind. <b>2012</b> , 12, 289-94		10
751	Role of TWEAK in lupus nephritis: a bench-to-bedside review. <b>2012</b> , 39, 130-42		95
750	[Description of hospital discharges in patients with systemic lupus erythematosus]. <b>2012</b> , 212, 432-9		1

749	Recent progress in the treatment of lupus nephritis. <b>2012</b> , 22, 803-813		7
748	SLE: serving the underserved in an academic medical center. <b>2012</b> , 51, 587-96		1
747	Utilizing registries in systemic lupus erythematosus clinical research. <b>2012</b> , 8, 353-60		10
746	Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2012</b> , 21, 682-7	2.6	22
745	Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. <b>2012</b> , 27, 3552-9		48
744	[Rheumatic diseases with primary onset in young adults: spondyloarthritis and connective tissue diseases]. <b>2012</b> , 53, 1038-46		1
743	Male versus female lupus: a comparison of ethnicity, clinical features, serology and outcome over a 30 year period. <i>Lupus</i> , <b>2012</b> , 21, 1041-8	2.6	30
742	[Renal involvement in systemic lupus erythematosus]. <b>2012</b> , 41, 260-6		2
741	Transcellular distribution heterogeneity of Annexin A5 represents a protective response to lupus-related thrombophilia: a pilot Proteomics-based study. <b>2012</b> , 420, 357-63		8
740	Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. <b>2012</b> , 64, 2975-85		102
739	Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <b>2012</b> , 64, 3364-73		81
738	Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. <b>2012</b> , 14, R221		119
737	Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. <b>2012</b> , 72, 1521-33		29
736	Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. <b>2012</b> , 8, 738-46		33
735	Opportunistic infections in systemic lupus erythematosus. <b>2012</b> , 7, 275-279		3
734	Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. <i>Lupus</i> , <b>2012</b> , 21, 386-401	2.6	51
733	Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients. <i>Rheumatology</i> , <b>2012</b> , 51, 2278-85	3.9	73
732	Survival analysis and causes of mortality in patients with lupus nephritis. <b>2012</b> , 27, 3248-54		151



731	Glucocorticoid use and abuse in SLE. <i>Rheumatology</i> , <b>2012</b> , 51, 1145-53	3.9	138
730	Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. <b>2012</b> , 14, R46		106
729	Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. <b>2012</b> , 14, R36		53
728	Recurrent very late stent thrombosis in a systemic lupus erythematosus patient. <b>2012</b> , 42, 118-21		1
727	B-cell depletion in the treatment of lupus nephritis. <b>2012</b> , 8, 505-14		61
726	Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. <b>2012</b> , 64, 2356-65		132
725	Genetic risk factors for thrombosis in systemic lupus erythematosus. <b>2012</b> , 39, 1603-10		19
724	Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?. <b>2012</b> , 14, 324-33		12
723	Recent advances in the treatment of lupus nephritis. <b>2012</b> , 16, 202-13		9
722	Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. <b>2012</b> , 143, 210-21		64
721	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <b>2012</b> , 11, 357-64		176
720	Massive ascites as a presenting feature of lupus. <i>International Journal of Rheumatic Diseases</i> , <b>2012</b> , 15, e15-6	2.3	9
719	[Diagnosis and treatment of lupus nephritis]. <b>2012</b> , 212, 147.e1-30		3
718	Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis. <b>2013</b> , 14, 63		43
717	Renal involvement in autoimmune connective tissue diseases. <b>2013</b> , 11, 95		69
716	Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. <b>2013</b> , 12, 1166-70		72
715	Clinical aspects of autoimmune rheumatic diseases. <b>2013</b> , 382, 797-808		130
714	Death-related factors of systemic lupus erythematosus patients associated with the course of disease in Chinese populations: multicenter and retrospective study of 1,958 inpatients. <b>2013</b> , 33, 1541-6		9

713	Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Effect on carotid intima-media thickness. <b>2013</b> , 72, 172-7		41
712	Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. <i>Lupus</i> , <b>2013</b> , 22, 1286-94	2.6	205
711	Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. <i>Lupus</i> , <b>2013</b> , 22, 810-8	2.6	30
710	Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. <b>2013</b> , 12, 410-5		54
709	Oxidative stress in the pathology and treatment of systemic lupus erythematosus. <b>2013</b> , 9, 674-86		196
708	Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. <i>Lupus</i> , <b>2013</b> , 22, 99-105	2.6	46
707	Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. <i>Lupus</i> , <b>2013</b> , 22, 1489-503	2.6	69
706	Interstitial inflammation and long-term renal outcomes in lupus nephritis. <i>Lupus</i> , <b>2013</b> , 22, 1446-54	2.6	40
705	Current management of lupus nephritis. <b>2013</b> , 27, 319-28		28
704	Targeted therapies in systemic lupus erythematosus. <i>Lupus</i> , <b>2013</b> , 22, 978-86	2.6	11
703	Procalcitonin kinetics: a reliable tool for diagnosis and monitoring of the course of bacterial infection in critically ill patients with autoimmune diseases. <b>2013</b> , 39, 2233-4		4
702	Is there a cure for systemic lupus erythematosus?. <i>Lupus</i> , <b>2013</b> , 22, 417-21	2.6	9
701	Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. <i>Lupus</i> , <b>2013</b> , 22, 1214-24	2.6	84
700	Management of infection in systemic lupus erythematosus. <b>2013</b> , 27, 377-89		21
699	Mortalit� au lupus � th� mateux syst� mique en France : analyse en causes multiples de d� t� . <b>2013</b> , 34, A54		
698	Incidence of progression from newly diagnosed systemic lupus erythematosus to end stage renal disease and all-cause mortality: a nationwide cohort study in Taiwan. <i>International Journal of Rheumatic Diseases</i> , <b>2013</b> , 16, 747-53	2.3	12
697	Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response. <i>Rheumatology</i> , <b>2013</b> , 52, 847-55	3.9	39
696	Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. <b>2013</b> , 149, 442-9		28

695	Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain. <i>Lupus</i> , <b>2013</b> , 22, 1118-27	2.6	38
694	The early cardiovascular changes in pediatric patients with systemic lupus erythematosus. <b>2013</b> , 28, 471-6		26
693	Total hip arthroplasty for vascular necrosis of the femoral head in patients with systemic lupus erythematosus: a midterm follow-up study of 28 hips in 24 patients. <b>2013</b> , 23, 73-9		18
692	Recent-onset systemic lupus erythematosus complicated by acute respiratory failure. <b>2013</b> , 65, 314-23		15
691	[Treatment of systemic lupus erythematosus: myths, certainties and doubts]. <b>2013</b> , 141, 533-42		8
690	Depression and systemic lupus erythematosus: a systematic review. <i>Lupus</i> , <b>2013</b> , 22, 409-16	2.6	123
689	Mood, anxiety and personality disorders in patients with systemic lupus erythematosus. <b>2013</b> , 54, 341-5		15
688	Skin nontuberculous mycobacterial infection in systemic lupus erythematosus: an unusual skin infection mimicking lupus vasculitis. <b>2013</b> , 42, 498-506		16
687	Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus. <i>Reumatología Clínica</i> , <b>2013</b> , 9, 359-64	0.9	11
686	Prognostic contributions of the underlying inflammatory disease and acute organ dysfunction in critically ill patients with systemic rheumatic diseases. <b>2013</b> , 24, e40-4		27
685	Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases. <b>2013</b> , 1		
684	Belimumab therapy in systemic lupus erythematosus. <b>2013</b> , 27, 225-35		6
683	Lupus Nephritis. <b>2013</b> , 561-575		
682	Global trends, potential mechanisms and early detection of organ damage in SLE. <b>2013</b> , 9, 301-10		51
681	Detection of Ro/SS-A antibodies in lupus erythematosus: what does it mean for the dermatologist?. <b>2013</b> , 68, 385-94		4
680	Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. <b>2013</b> , 46, 363-8		23
679	Experiences and perspectives of adults living with systemic lupus erythematosus: thematic synthesis of qualitative studies. <b>2013</b> , 65, 1752-65		89
678	FcγRIIIa ligation induces platelet hypersensitivity to thrombotic stimuli. <b>2013</b> , 182, 244-54		21

677	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). <b>2013</b> , 72, 1786-92		126
676	Incidence of Cancer in a Cohort of Spanish Patients With Systemic Lupus Erythematosus. <b>2013</b> , 9, 359-364		
675	Traitement du lupus ^ lyth^ mateux syst^ mique. <b>2013</b> , 73-90		
674	All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. <i>Rheumatology</i> , <b>2013</b> , 52, 905-9	3.9	76
673	Review of refractory lupus nephritis. <b>2013</b> , 8, 61-72		2
672	Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. <b>2013</b> , 46, 537-46		7
671	Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study. <i>Lupus</i> , <b>2013</b> , 22, 919-27	2.6	40
670	Systemic lupus erythematosus diagnostics in the 'omics' era. <b>2013</b> , 8, 671-687		32
669	Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. <i>Lupus</i> , <b>2013</b> , 22, 1425-30	2.6	49
668	Validation and evaluation of the German Brief Index of Lupus Damage (BILD)--a self-reported instrument to record damage in systemic lupus erythematosus. <i>Lupus</i> , <b>2013</b> , 22, 1050-5	2.6	9
667	Systemic lupus erythematosus (SLE) in the eastern region of Saudi Arabia. A comparative study. <i>Lupus</i> , <b>2013</b> , 22, 1529-33	2.6	16
666	Damage in lupus patients--what have we learned so far?. <i>Lupus</i> , <b>2013</b> , 22, 1225-31	2.6	12
665	Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. <i>Lupus</i> , <b>2013</b> , 22, 106-11	2.6	42
664	Temporal trends in characteristics and outcome of intensive care unit patients with systemic lupus erythematosus in Taiwan: a national population-based study. <i>Lupus</i> , <b>2013</b> , 22, 644-52	2.6	13
663	Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. <i>Lupus</i> , <b>2013</b> , 22, 268-78	2.6	26
662	Clinical Aspects of the Nervous System. <b>2013</b> , 368-381		3
661	Predicting Sj^ gren's syndrome in patients with recent-onset SLE. <i>Rheumatology</i> , <b>2013</b> , 52, 1438-42	3.9	13
660	Extent and characteristics of self-reported pain in patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2013</b> , 22, 136-43	2.6	19

659	Towards treating lupus nephritis without oral steroids: a dream-come-true?. <b>2013</b> , 72, 1271-2		5
658	Stochastic differential equation modeling the prevalence of rare chronic diseases with an application to systemic lupus erythematosus. <b>2013</b> , 67, 202-210		1
657	Genetic determinants of plasma Eglycoprotein I levels: a genome-wide association study in extended pedigrees from Spain. <b>2013</b> , 11, 521-8		8
656	Delta neutrophil index as a marker for differential diagnosis between flare and infection in febrile systemic lupus erythematosus patients. <i>Lupus</i> , <b>2013</b> , 22, 1102-9	2.6	26
655	Influenza vaccination in autoimmune rheumatic disease patients. <b>2013</b> , 229, 29-34		20
654	Features and outcomes of lupus nephritis in Morocco: analysis of 114 patients. <b>2013</b> , 6, 249-58		15
653	Cardiopulmonary Disease in SLE. <b>2013</b> , 352-362		
652	SLE and Infections. <b>2013</b> , 555-562.e1		1
651	Adjunctive and Preventive Measures. <b>2013</b> , 633-639		
650	Overview and Clinical Presentation. <b>2013</b> , 304-309		2
649	Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus. <b>2014</b> , 9, e98883		21
648	Lupus-prone mice fail to raise antigen-specific T cell responses to intracellular infection. <b>2014</b> , 9, e111382		20
647	Renal Involvement in Children with Systemic Lupus Erythematosus. <b>2014</b> , 1-45		
646	Infections increase risk of arterial and venous thromboses in Danish patients with systemic lupus erythematosus: 5102 patient-years of followup. <b>2014</b> , 41, 1817-22		3
645	Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. <i>Lupus</i> , <b>2014</b> , 23, 1512-6	2.6	51
644	Sirukumab : a novel therapy for lupus nephritis?. <b>2014</b> , 23, 1449-55		13
643	Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 576	8.4	82
642	Early diagnosis and treatment of steroid-induced diabetes mellitus in patients with rheumatoid arthritis and other connective tissue diseases. <b>2014</b> , 24, 52-9		16

641	A cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. <i>Rheumatology</i> , <b>2014</b> , 53, 138-44	3.9	13
640	Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 629	8.4	57
639	A case of systemic lupus erythematosus presenting with an acute abdomen: successful treatment with steroid. <b>2014</b> , 2014, 318939		1
638	Renal transplantation in systemic lupus erythematosus: outcome and prognostic factors in 50 cases from a single centre. <b>2014</b> , 2014, 746192		16
637	Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients. <b>2014</b> , 66, 725-31		18
636	Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. <b>2014</b> , 111, E5302-11		79
635	Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. <b>2014</b> , 66, 3359-70		62
634	Micofenolato o tacrolimus comparado con ciclofosfamida en el tratamiento de nefritis l�tica: revisi�n sistem�tica y metaan�lisis. <i>Revista Colombiana De Reumatolog�a</i> , <b>2014</b> , 21, 213-225	0.2	1
633	Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. <b>2014</b> , 66, 617-24		30
632	Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. <b>2014</b> , 12, 452-8		53
631	Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. <b>2014</b> , 7, 1033-46		51
630	Major adverse cardiovascular events and mortality in systemic lupus erythematosus patients after successful delivery: a population-based study. <b>2014</b> , 347, 42-9		14
629	Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus. <b>2014</b> , 2014, 731806		9
628	Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test. <b>2014</b> , 2014, 291031		8
627	Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. <b>2014</b> , 23, 1656-68		50
626	Secondary antibody deficiency. <b>2014</b> , 10, 583-91		29
625	Prognostic Factors for Treatment Response in Patients With Lupus Nephritis. <b>2014</b> , 10, 164-169		0
624	Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematosus accelerate carotid arteries intima-media thickness changes?. <b>2014</b> , 34, 321-7		10

623	Role of peroxynitrite-modified biomolecules in the etiopathogenesis of systemic lupus erythematosus. <b>2014</b> , 14, 1-11		28
622	Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. <b>2014</b> , 5, 510-8		32
621	Trends in systemic lupus erythematosus mortality in Spain from 1981 to 2010. <i>Lupus</i> , <b>2014</b> , 23, 431-5	2.6	17
620	Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. <b>2014</b> , 66, 2297-307		80
619	Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. <b>2014</b> , 41, 680-7		129
618	Ten common mistakes in the management of lupus nephritis. <i>American Journal of Kidney Diseases</i> , <b>2014</b> , 63, 667-76	7.4	28
617	Anti-B cell antibody therapies for inflammatory rheumatic diseases. <b>2014</b> , 65, 263-78		26
616	Pragmatic approaches to therapy for systemic lupus erythematosus. <b>2014</b> , 10, 97-107		65
615	Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding. <b>2014</b> , 66, 2259-69		8
614	Mucocutaneous manifestations in a UK national cohort of juvenile-onset systemic lupus erythematosus patients. <i>Rheumatology</i> , <b>2014</b> , 53, 1504-12	3.9	22
613	[Assessing the cardiovascular risk in patients with systemic lupus erythematosus]. <b>2014</b> , 35, 723-9		4
612	The clinical significance of serial kidney biopsies in lupus nephritis. <b>2014</b> , 24, 453-6		13
611	Anti-C1q autoantibodies from active lupus nephritis patients could inhibit the clearance of apoptotic cells and complement classical pathway activation mediated by C1q in vitro. <b>2014</b> , 219, 980-9		31
610	Invasive fungal disease in systemic lupus erythematosus: a systematic review of disease characteristics, risk factors, and prognosis. <b>2014</b> , 44, 325-30		41
609	Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. <b>2014</b> , 41, 300-9		118
608	Rituximab and lupus--a promising pair?. <b>2014</b> , 16, 444		5
607	Biologics in systemic lupus erythematosus: current options and future perspectives. <b>2014</b> , 75, 440, 442-7		7
606	[Atherosclerosis in systemic lupus erythematosus]. <b>2014</b> , 43, 1034-47		9

605	Vaccines and biologics. <b>2014</b> , 73, 1446-54		22
604	Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center. <b>2014</b> , 33, 947-53		22
603	Emerging role of SIGIRR rs7396562(T/G) polymorphism in systemic lupus erythematosus in a Chinese population. <b>2014</b> , 37, 1847-51		9
602	Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. <b>2014</b> , 58, 1587-98		37
601	[Proliferative lupus nephritis treatment: practice survey in nephrology and internal medicine in France]. <b>2014</b> , 10, 170-6		1
600	Ultrasonographic evaluation of renal resistive index in patients with lupus nephritis: correlation with histologic findings. <b>2014</b> , 40, 2573-80		9
599	Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008. <i>Lupus</i> , <b>2014</b> , 23, 1430-4	2.6	25
598	Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. <b>2014</b> , 66, 2503-11		114
597	Patterns of systemic lupus erythematosus expression in Europe. <b>2014</b> , 13, 621-9		53
596	Anti-nucleosome antibodies: A potential surrogate marker for renal affection in lupus patients with insignificant proteinuria. <b>2014</b> , 36, 79-84		10
595	Challenges for lupus management in emerging countries. <b>2014</b> , 43, e209-20		16
594	Which dose of steroids and which cytotoxics for severe lupus?. <b>2014</b> , 43, e157-65		3
593	Impact of race and ethnicity in the course and outcome of systemic lupus erythematosus. <b>2014</b> , 40, 433-54, vii-viii		45
592	Prognostic factors for treatment response in patients with lupus nephritis. <i>Reumatología Clínica</i> , <b>2014</b> , 10, 164-9	0.9	6
591	Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1183	1.8	71
590	Screening for Anal Cancer in Women. <b>2015</b> , 19, S27-42		89
589	Comparative Assessment of Different Health Utility Measures in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , <b>2015</b> , 5, 13297	4.9	6
588	Update on the management of lupus nephritis. <b>2015</b> , 12, 10-15		



587	The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamide Synergistically Suppress Murine Lupus Nephritis. <b>2015</b> , 67, 1858-67		14
586	Brief Report: Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus. <b>2015</b> , 67, 3219-25		78
585	Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners. <b>2015</b> , 9, OE01-4		2
584	Pulmonary hemorrhage as an unusual initial manifestation of systemic lupus erythematosus. <b>2015</b> , 3, 370		
583	Lupus or syphilis? That is the question!. <b>2015</b> , 2015,		7
582	[Systemic lupus and kidney disease: contribution of anti-SSA]. <b>2015</b> , 20, 39		
581	Renal Interstitial Arteriosclerotic Lesions in Lupus Nephritis Patients: A Cohort Study from China. <b>2015</b> , 10, e0141547		12
580	Clinicopathological correlation in asian patients with biopsy-proven lupus nephritis. <b>2015</b> , 2015, 857316		12
579	The Diagnosis and Treatment of Systemic Lupus Erythematosus. <b>2015</b> , 112, 423-32		81
578	HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response. <b>2015</b> , 2015, 946748		41
577	The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. <b>2015</b> , 2015, 106904		48
576	Anti-C1q antibodies as a follow-up marker in SLE patients. <b>2015</b> , 10, e0123572		38
575	Early Lupus Project - A multicentre Italian study on systemic lupus erythematosus of recent onset. <i>Lupus</i> , <b>2015</b> , 24, 1276-82	2.6	12
574	What is the risk of having a total hip or knee replacement for patients with lupus?. <i>Lupus</i> , <b>2015</b> , 24, 198-202		11
573	Pathogenesis of Neuropsychiatric Syndromes of Systemic Lupus Erythematosus. <b>2015</b> , 05, 46-56		3
572	Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases. <b>2015</b> , 25, 335-43		8
571	Survival Disparity of African American Versus Non-African American Patients With ESRD Due to SLE. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 630-7	7.4	30
570	Achilles tendinitis in systemic lupus erythematosus: search for an associated inflammatory disease. <i>Lupus</i> , <b>2015</b> , 24, 1318-20	2.6	2

569	Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. <b>2015</b> , 1, e000168		55
568	Lupus eritematoso sist <sup>^</sup> mico asociado al consumo cr <sup>^</sup> ñico de coca <sup>^</sup> ñia. <i>Revista Colombiana De Reumatolog<sup>í</sup>a</i> , <b>2015</b> , 22, 174-179	0.2	2
567	Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients. <i>Lupus</i> , <b>2015</b> , 24, 816-21	2.6	13
566	CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?. <b>2015</b> , 179, 85-9		40
565	Lymphocytes and Infection in Autoimmune Diseases. <b>2015</b> , 109-131		
564	Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis. <b>2015</b> , 67, 1453-62		38
563	Influenza A (H1N1) virus infection triggers severe pulmonary inflammation in lupus-prone mice following viral clearance. <b>2015</b> , 57, 66-76		7
562	Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000058	4.6	37
561	Twenty-year brain magnetic resonance imaging follow-up study in Systemic Lupus Erythematosus: Factors associated with accrual of damage and central nervous system involvement. <b>2015</b> , 14, 510-6		28
560	Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre. <i>Lupus</i> , <b>2015</b> , 24, 331-8	2.6	22
559	Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever. <b>2015</b> , 14, 586-93		28
558	Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000061	4.6	22
557	Systemic lupus erythematosus and thrombosis. <b>2015</b> , 13, 16		38
556	Clinical aspects of indirect immunofluorescence for autoimmune diseases. <b>2015</b> , 11, 597-616		3
555	[Clinical evaluation of the new screening procedures for hydroxychloroquine retinopathy, according to the American Academy of Ophthalmology guidelines. Prospective study of 184 patients]. <b>2015</b> , 38, 377-87		1
554	Spectrum of infections and outcome among hospitalized South Africans with systemic lupus erythematosus. <b>2015</b> , 34, 479-88		21
553	Colony-stimulating factor-1: a potential biomarker for lupus nephritis. <b>2015</b> , 26, 379-89		36
552	Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. <b>2015</b> , 7, 255-70		4

551	[Interstitial nephritis in rheumatic diseases]. <b>2015</b> , 74, 290-9		3
550	Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011. <b>2015</b> , 67, 1078-85		98
549	Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. <b>2015</b> , 67, 1577-85		123
548	Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 1143-9	2.6	9
547	Targeting interferons in systemic lupus erythematosus: current and future prospects. <b>2015</b> , 75, 835-46		48
546	Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility. <b>2015</b> , 70, 196-210		32
545	Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. <i>Lupus</i> , <b>2015</b> , 24, 1468-78	2.6	36
544	Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study. <b>2015</b> , 9, 1096-107		33
543	CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice. <b>2015</b> , 117, 732-7		14
542	The regional function of cGAS/STING signal in multiple organs: One of culprit behind systemic lupus erythematosus?. <b>2015</b> , 85, 846-9		13
541	Implementing Big Data analytics to predict Systemic Lupus Erythematosus. <b>2015</b> ,		3
540	The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study. <b>2015</b> , 45, 195-201		40
539	Improving Pneumococcal Vaccination in Pediatric Rheumatology Patients. <b>2015</b> , 136, e681-6		24
538	Risk of Stroke in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <b>2015</b> , 24, 2774-80		25
537	Genetics of Lupus Nephritis: Clinical Implications. <b>2015</b> , 35, 396-409		29
536	The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis. <b>2015</b> , 35, 455-64		48
535	Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases. <b>2015</b> , 44, 777-802		13
534	Prevalence and severity of depression and anxiety in patients with systemic lupus erythematosus: An epidemiologic study in Iranian patients. <b>2015</b> , 25, 405-9		13

533	Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. <i>Lupus</i> , <b>2015</b> , 24, 299-306	2.6	12
532	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <b>2015</b> , 74, 1011-8		369
531	Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. <b>2015</b> , 14, 153-9		87
530	Limitations of standard immunosuppressive treatment in ANCA-associated vasculitis and lupus nephritis. <b>2014</b> , 128, 205-15		15
529	[Lupus nephritis: up-to-date]. <b>2015</b> , 36, 98-106		
528	Purtscher-like Retinopathy Associated with Systemic Lupus Erythematosus. <b>2016</b> , 24, 60-8		10
527	Infections in Early Systemic Lupus Erythematosus Pathogenesis. <b>2016</b> , 191-197		1
526	Systemic Lupus Erythematosus and Infections. <b>2016</b> , 403-410		1
525	CXCL13 Promotes Proliferation of Mesangial Cells by Combination with CXCR5 in SLE. <b>2016</b> , 2016, 2063985		9
524	Changes to fibrinolysis in patients with systemic lupus erythematosus are associated with endothelial cell damage and inflammation, but not antiphospholipid antibodies. <b>2016</b> , 27, 870-875		4
523	Pentraxin 3 Is Closely Associated With Tubulointerstitial Injury in Lupus Nephritis: A Large Multicenter Cross-Sectional Study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2520	1.8	22
522	Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. <b>2016</b> , 184, 11-8		17
521	Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation. <b>2016</b> , 68, 2740-2751		12
520	The Spectrum of Cutaneous Manifestations in Systemic Lupus Erythematosus and Novel Classification. <b>2016</b> , 77-94		1
519	Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context. <b>2016</b> , 68, 1787-1794		13
518	Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. <i>Rheumatology</i> , <b>2017</b> , 56, 477-487	3.9	21
517	Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice. <b>2016</b> , 16, 448		8
516	Secondary antibody deficiency - causes and approach to diagnosis. <b>2016</b> , 16, 571-576		22

515	Overview of pathophysiology and treatment of human lupus nephritis. <b>2016</b> , 28, 460-7		12
514	Hot topics in lupus nephropathy: Responses from a new 2015 Spanish guideline. <b>2016</b> , 36, 333-338		1
513	Estudio de la concordancia entre la opini�n cl�nica de los reumat�logos con respecto a la necesidad de inmunosupresi�n y el resultado de la biopsia renal en pacientes adultos con nefritis l�pica. <i>Revista Colombiana De Reumatolog�a</i> , <b>2016</b> , 23, 73-78	0.2	
512	Predictors of musculoskeletal flares and Jaccoud's arthropathy in patients with systemic lupus erythematosus: A 5-year prospective study. <b>2016</b> , 46, 217-224		18
511	Clinical outcomes of lupus nephritis patients with different proportions of crescents. <i>Lupus</i> , <b>2016</b> , 25, 1532-1541	2.6	12
510	Conventional Treatment of Systemic Lupus Erythematosus. <b>2016</b> , 213-238		
509	The problems and pitfalls in systemic lupus erythematosus drug discovery. <b>2016</b> , 11, 525-7		5
508	Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis. <b>2016</b> , 43, 1801-1815		19
507	Study of the agreement between clinical opinion of rheumatologists regarding the need for immunosuppression and the result of renal biopsy in adult patients with lupus nephritis. <i>Revista Colombiana De Reumatolog�a (English Edition)</i> , <b>2016</b> , 23, 73-78	0.1	
506	Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis. <b>2016</b> , 90, 1357-1367		14
505	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. <b>2016</b> , 15, 1120-1124		147
504	Why targeted therapies are necessary for systemic lupus erythematosus. <i>Lupus</i> , <b>2016</b> , 25, 1070-9	2.6	17
503	Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. <b>2016</b> , 68, 1432-41		183
502	The risk of cancer in patients with connective tissue diseases but without dermatomyositis or polymyositis: A multicenter cohort study conducted over 15 years in China. <b>2016</b> , 177, 70-4		3
501	Systemic lupus erythematosus today. <b>2016</b> , 146, 160-162		
500	Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. <b>2016</b> , 14, 137		79
499	The diagnosis and management of the haematologic manifestations of lupus. <b>2016</b> , 74, 139-160		53
498	Current Perspectives on Arthroplasty in Systemic Lupus Erythematosus: Rates, Outcomes, and Adverse Events. <b>2016</b> , 18, 59		13

497	Risk of end-stage renal disease in systemic lupus erythematosus patients: a nationwide population-based study. <i>International Journal of Rheumatic Diseases</i> , <b>2016</b> , 19, 1175-1182	2.3	10
496	Distinguishing infections vs flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2017</b> , 56, i46-i54	3.9	24
495	Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. <b>2016</b> , 18, 243		7
494	Development and validation of a simple lupus severity index using ACR criteria for classification of SLE. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000136	4.6	18
493	A pilot investigation of the prevalence of US-detectable forefoot joint pathology and reported foot-related disability in participants with systemic lupus erythematosus. <b>2016</b> , 9, 27		13
492	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3748	1.8	43
491	Lupusnephritis. <b>2016</b> , 11, 134-141		
490	Current and Emerging Therapies for Lupus Nephritis. <b>2016</b> , 27, 2929-2939		55
489	Hot topics in lupus nephropathy: Responses from a new 2015 Spanish guideline. <b>2016</b> , 36, 333-8		
488	Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. <b>2016</b> , 169, 58-68		47
487	Anti-dsDNA antibodies bind to TLR4 and activate NLRP3 inflammasome in lupus monocytes/macrophages. <b>2016</b> , 14, 156		59
486	Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 1623-30	3.9	24
485	Immunomodulation by classical conditioning in NZB/W (F1) mice: Lifespan and diurnal variation. <b>2016</b> , 9, 40-6		
484	Protein arrays for biomarker discovery in lupus. <b>2016</b> , 10, 625-34		10
483	Lupus nephritis: When and how often to biopsy and what does it mean?. <b>2016</b> , 74, 27-40		35
482	Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases. <b>2016</b> , 43, 267-72		19
481	Venous and Arterial Thrombotic Events in Systemic Lupus Erythematosus. <b>2016</b> , 43, 576-86		24
480	The spectrum of nephrocutaneous diseases and associations: Inflammatory and medication-related nephrocutaneous associations. <b>2016</b> , 74, 247-70; quiz 271-2		4

479	Lupus erythematosus revisited. <b>2016</b> , 38, 97-112		32
478	Mortality in Systemic Lupus Erythematosus: an Updated Review. <b>2016</b> , 18, 21		84
477	Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. <b>2016</b> , 15, 786-94		19
476	Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4-Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus. <b>2016</b> , 68, 164-73		35
475	Patient-Reported Outcomes in Systemic Lupus Erythematosus. <b>2016</b> , 42, 253-263		32
474	Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007. <i>Lupus</i> , <b>2016</b> , 25, 666-70	2.6	6
473	[Prevention of infections in adults and adolescents with systemic lupus erythematosus: Guidelines for the clinical practice based on the literature and expert opinion]. <b>2016</b> , 37, 307-20		10
472	Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus. <b>2016</b> , 26, 562-8		8
471	[Systemic lupus erythematosus today]. <b>2016</b> , 146, 160-2		
470	Salivary proteomics: A new adjuvant approach to the early diagnosis of familial juvenile systemic lupus erythematosus. <b>2016</b> , 89, 97-100		16
469	Connective tissue diseases, multimorbidity and the ageing lung. <b>2016</b> , 47, 1535-58		20
468	Traditional Chinese medicine therapy improves the survival of systemic lupus erythematosus patients. <b>2016</b> , 45, 596-603		21
467	Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. <b>2016</b> , 15, 93-101		87
466	Outcome of lupus glomerulonephritis: the role of prospective observational cohort studies. <i>Rheumatology</i> , <b>2016</b> , 55, 195-6	3.9	4
465	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
464	Circulating cell free DNA as a predictor of systemic lupus erythematosus severity and monitoring of therapy. <b>2016</b> , 17, 79-85		7
463	Comorbidities of pediatric systemic lupus erythematosus: A 6-year nationwide population-based study. <b>2016</b> , 49, 257-63		19
462	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. <b>2016</b> , 26, 80-6		28

461	Lupus nephritis management guidelines compared. <b>2016</b> , 31, 904-13		71
460	Clinical and immunological characteristics in 552 systemic lupus erythematosus patients in a southern province of China. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 68-75	2.3	9
459	[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]. <b>2017</b> , 76, 27-32		0
458	Research on biological therapies in systemic lupus erythematosus. <b>2017</b> , 148, 67-68		
457	Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial. <b>2017</b> , 18, 53		8
456	[Systemic lupus erythematosus and contraception: A systematic literature review]. <b>2017</b> , 38, 358-367		5
455	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. <b>2017</b> , 47, 38-45		80
454	Prognosis in Antiphospholipid Syndrome. <b>2017</b> , 12, 281-294		
453	Lupus eritematoso sist^mico (l). Etiopatogenia. Manifestaciones cl^nicas. Historia natural. Pruebas diagn^sticas. Diagn^stico diferencial. <b>2017</b> , 12, 1429-1439		
452	Carotid intima-media thickness and arterial stiffness in pediatric systemic lupus erythematosus. <i>Lupus</i> , <b>2017</b> , 26, 989-995	2.6	7
451	Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry. <i>Lupus</i> , <b>2017</b> , 26, 881-885	2.6	15
450	Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study. <b>2017</b> , 39, 465-473		11
449	Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. <b>2017</b> , 76, 1544-1549		61
448	Description of Malignancy Rates in Childhood- and Adult-Onset Systemic Lupus Erythematosus by Proportional Meta-analysis. <b>2017</b> , 23, 187-192		1
447	Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses. <b>2017</b> , 37, 1089-1099		24
446	The evolving concept of SLE comorbidities. <b>2017</b> , 13, 753-768		23
445	Epidemiology of systemic lupus erythematosus. <b>2017</b> , 13, 799-814		92
444	Components of quality of life in a sample of patients with lupus: a confirmatory factor analysis and Rasch modeling of the LupusQoL. <b>2017</b> , 36, 1789-1795		6



443	Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre. <b>2017</b> , 16, 750-755		29
442	Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. <i>Lupus</i> , <b>2017</b> , 26, 1564-1570	2.6	16
441	Profiles of Long Noncoding RNAs in Human Naive and Memory T Cells. <b>2017</b> , 199, 547-558		21
440	Clinical pattern in Egyptian systemic lupus erythematosus patients with pleuropulmonary involvement. <b>2017</b> , 39, 83-88		5
439	Research on biological therapies in systemic lupus erythematosus. <b>2017</b> , 148, 67-68		
438	Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. <b>2017</b> , 47, 204-215		55
437	Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry. <b>2017</b> , 44, 452-458		5
436	Genital Mycoplasma infection among Mexican women with systemic lupus erythematosus. <b>2017</b> , 138, 17-22		7
435	Mindfulness-based group therapy for systemic lupus erythematosus: A first exploration of a promising mind-body intervention. <b>2017</b> , 26, 73-75		4
434	Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus. <b>2017</b> , 9, 57-70		8
433	Childhood versus adult-onset systemic lupus erythematosus: long-term outcome and predictors of mortality. <b>2017</b> , 36, 343-350		15
432	Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. <b>2017</b> , 46, 263-272		9
431	Mortality from systemic erythematosus lupus in Brazil: evaluation of causes according to the government health database. <b>2017</b> , 57, 574-582		4
430	Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. <i>Rheumatology</i> , <b>2017</b> , 56, 2212-2221	3.9	13
429	Impact of Sex on Systemic Lupus Erythematosus-Related Causes of Premature Mortality in the United States. <b>2017</b> , 26, 1214-1221		11
428	Characterization of the thrombin generation profile in systemic lupus erythematosus. <b>2017</b> , 104, 35-41		5
427	Mortalidade por l <sup>u</sup> s eritematoso sist <sup>ê</sup> mico no Brasil: avalia <sup>ç</sup> o <sup>ẽ</sup> das causas de acordo com o banco de dados de sa <sup>u</sup> de do governo. <b>2017</b> , 57, 574-582		5
426	Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. <b>2017</b> , 35, 4877-4885		27

425	Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. <i>Lupus</i> , <b>2017</b> , 26, 1463-1472	2.6	26
424	Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. <b>2017</b> , 31, 334-341		28
423	Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e0001734.6		14
422	A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice. <i>Scientific Reports</i> , <b>2017</b> , 7, 16642	4.9	24
421	A review on SLE and malignancy. <b>2017</b> , 31, 373-396		34
420	Associates and predictors of pleurisy or pericarditis in SLE. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e0002214.6		27
419	The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus. <b>2017</b> , 3, 308-321		11
418	HOSPITALIZAÇÃO DE PACIENTES COM LUPUS ERITEMATOSO SISTÊMICO DURANTE UM PERÍODO DE 10 ANOS. <b>2017</b> , 57, S162		
417	VASCULITE DE ARTÉRIA CEREBRAL MÚLTIPLA ASSOCIADA A AFASIA GLOBAL SÍMBITA COMO MANIFESTAÇÃO PRECOCE DO LÚPUS ERITEMATOSO SISTÊMICO: RELATO DE CASO. <b>2017</b> , 57, S206-S207		
416	Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years. <b>2017</b> , 44, 1375-1383		23
415	Comparison of ethnicity, gender, age of onset and outcome in South Africans with systemic lupus erythematosus. <i>Lupus</i> , <b>2017</b> , 26, 438-446	2.6	14
414	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <b>2017</b> , 76, 10-20		91
413	Cortical Thickness and Episodic Memory Impairment in Systemic Lupus Erythematosus. <b>2017</b> , 27, 122-127		3
412	Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse. <b>2017</b> , 23, 988-994		5
411	Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. <b>2017</b> , 69, 148-160		131
410	ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism. <b>2017</b> , 19, D309-D332		8
409	Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?. <b>2017</b> , 102, 4421-4427		27
408	Clinical features and antinuclear antibodies profile among adults with systemic lupus erythematosus and lupus nephritis: a cross-sectional study. <b>2017</b> , 27, 114		6

407	46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study. <b>2017</b> , 167, 777-785		75
406	Purified umbilical cord derived mesenchymal stem cell treatment in a case of systemic lupus erythematosus. <b>2017</b> , 6, 31		7
405	Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. <b>2018</b> , 45, 671-677		22
404	Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice. <b>2018</b> , 15, 1800-1813		9
403	Atherosclerosis and autoimmunity: a growing relationship. <i>International Journal of Rheumatic Diseases</i> , <b>2018</b> , 21, 908-921	2.3	27
402	The clinical manifestations and response to treatment in South Africans with lupus nephritis. <i>Lupus</i> , <b>2018</b> , 27, 1207-1217	2.6	4
401	The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective GIRCS study: GIRCS=Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale. <i>Medicine (United States)</i> , <b>2018</b> , 97, e0370	1.8	4
400	Hematologic Manifestations of Childhood Illness. <b>2018</b> , 2215-2237.e9		0
399	Infections in hospitalized lupus nephritis patients: characteristics, risk factors, and outcomes. <i>Lupus</i> , <b>2018</b> , 27, 1150-1158	2.6	10
398	Intravenous pulses of methylprednisolone to treat flares of immune-mediated diseases: how much, how long?. <i>Lupus</i> , <b>2018</b> , 27, 1177-1184	2.6	4
397	Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. <b>2018</b> , 28, 986-992		28
396	Splenectomy in systemic lupus erythematosus and autoimmune hematologic disease: a comparative analysis. <b>2018</b> , 37, 943-948		5
395	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. <b>2018</b> , 77, 355-363		100
394	Impaired contraction of blood clots as a novel prothrombotic mechanism in systemic lupus erythematosus. <b>2018</b> , 132, 243-254		22
393	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , <b>2018</b> , 57, e1-e45	3.9	150
392	Association of Tumor Necrosis Factor Alpha-Induced Protein 3 Interacting Protein 1 (TNIP1) Gene Polymorphism (rs7708392) with Lupus Nephritis in Egyptian Patients. <b>2018</b> , 56, 478-488		6
391	Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS. <i>Lupus</i> , <b>2018</b> , 27, 1130-1139	2.6	14
390	[Cardiovascular disease in lupus nephritis: An underestimated risk]. <b>2018</b> , 35, 51-53		

389	Pulmonary manifestation as initial presentation for systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , <b>2018</b> , 21, 1322-1325	2.3	3
388	Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus. <b>2018</b> , 18, 109-117		11
387	Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. <i>Lupus</i> , <b>2018</b> , 27, 225-234	2.6	17
386	Late-onset systemic lupus erythematosus: Is it "mild lupus"?. <i>Lupus</i> , <b>2018</b> , 27, 235-242	2.6	14
385	Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. <b>2018</b> , 70, 582-591		40
384	The correlation of urinary podocytes and podocalyxin with histological features of lupus nephritis. <i>Lupus</i> , <b>2018</b> , 27, 484-493	2.6	7
383	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. <b>2018</b> , 70, 266-276		114
382	Disease trends over time and CD4CCR5 T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. <b>2018</b> , 28, 53-63		19
381	Risk of damage and mortality in SLE patients fulfilling the ACR or only the SLICC classification criteria. A 10-year, inception cohort study. <i>Lupus</i> , <b>2018</b> , 27, 556-563	2.6	6
380	Regulatory T cells in acute and chronic kidney diseases. <b>2018</b> , 314, F679-F698		34
379	Brain magnetic resonance imaging, cerebrospinal fluid, and autoantibody profile in 118 patients with neuropsychiatric lupus. <b>2018</b> , 37, 227-233		12
378	Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic. <b>2018</b> , 77, 727-734		14
377	A Population-based Study of Perinatal Infection Risk in Women with and without Systemic Lupus Erythematosus and their Infants. <b>2018</b> , 32, 81-89		7
376	Management of vaccination in rheumatic disease. <b>2018</b> , 32, 720-734		4
375	Case of severe acute lupus myocarditis and multiple-organ failure. <b>2018</b> , 2018,		2
374	Acute Hepatic Failure and Epididymitis in a Hispanic Patient With Active Systemic Lupus Erythematosus. <b>2018</b> , 10, 722-724		
373	Organ damage in a cohort of Colombian patients with systemic lupus erythematosus: Characterization and associated factors. <i>Revista Colombiana De Reumatología (English Edition)</i> , <b>2018</b> , 25, 85-91	0.1	
372	Vaccination in SLE patients. <i>Lupus</i> , <b>2018</b> , 27, 36-39	2.6	1

371	In lupus nephritis, how do extracellular DNAs trigger type I interferon secretion: Under the assistance of HMGB1-cGAS?. <b>2018</b> , 121, 51-53		1
370	Systemic lupus erythematosus is a risk factor for cardiovascular disease: a nationwide, population-based study in Korea. <i>Lupus</i> , <b>2018</b> , 27, 2050-2056	2.6	10
369	Inhibition of microRNA-182-5p contributes to attenuation of lupus nephritis via Foxo1 signaling. <b>2018</b> , 373, 91-98		9
368	Circulating Angiogenic T Cells Are Increased in Lupus Nephritis Patients. <b>2018</b> , 24, 5384-5390		8
367	Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. <b>2018</b> , 154, 1432-1440		27
366	Pneumonia in patients with systemic lupus erythematosus: Epidemiology, microbiology and outcomes. <i>Lupus</i> , <b>2018</b> , 27, 1953-1959	2.6	9
365	The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. <b>2018</b> , 459, 11-19		40
364	Spectrum of clinical manifestations of SLE patients from India and its correlation with KIR gene polymorphism. <b>2018</b> , 17, 99-107		
363	Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. <i>Lupus</i> , <b>2018</b> , 27, 1431-1436	2.6	34
362	Clinical and immunological pattern and outcome of Egyptian systemic lupus erythematosus patients: a single center experience. <i>Lupus</i> , <b>2018</b> , 27, 1562-1569	2.6	11
361	Pathology of Neuropsychiatric Systemic Lupus Erythematosus. <b>2018</b> , 43-58		1
360	Important considerations in pregnant patients with lupus nephritis. <b>2018</b> , 14, 489-498		4
359	Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases. <b>2018</b> , 5217461		2
358	Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events. <i>Lupus</i> , <b>2018</b> , 27, 1509-1516	2.6	8
357	Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2018</b> , 27, 1644-1651	2.6	19
356	T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients. <b>2017</b> , 51, e4547		9
355	Do Death Certificates Underestimate the Burden of Rare Diseases? The Example of Systemic Lupus Erythematosus Mortality, Sweden, 2001-2013. <b>2018</b> , 133, 481-488		13
354	Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1876	8.4	7

353	Autoimmune Diseases and Their Manifestations on Oral Cavity: Diagnosis and Clinical Management. <b>2018</b> , 2018, 6061825		28
352	Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus. <b>2018</b> , 37, 2699-2705		14
351	Atherosclerosis and renal disease involvement in patients with systemic lupus erythematosus: a cross-sectional cohort study. <i>Rheumatology</i> , <b>2018</b> , 57, 1964-1971	3.9	6
350	Kollagenosen im Kindes- und Jugendalter. <b>2018</b> , 166, 562-571		
349	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. <b>2018</b> , 20, 36		9
348	White-matter integrity in patients with systemic lupus erythematosus and memory deficits. <b>2018</b> , 31, 587-595		10
347	Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis. <i>International Journal of Rheumatic Diseases</i> , <b>2018</b> , 21, 1163-1172	2.3	11
346	Procalcitonin and C-reactive protein as markers of infection in systemic lupus erythematosus: the controversy continues. <i>Lupus</i> , <b>2019</b> , 28, 1329-1336	2.6	11
345	Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort. <b>2019</b> , 38, 107-115		26
344	Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. <b>2019</b> , 48, 840-846		12
343	[Epidemiology of systemic lupus erythematosus in Reunion Island, Indian Ocean: A case-series in adult patients from a University Hospital]. <b>2019</b> , 40, 214-219		3
342	Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti-β2-Glycoprotein I and Small Dense High-Density Lipoprotein Particles. <b>2019</b> , 71, 116-125		7
341	Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1626	8.4	12
340	Outcome and Prognosis of Patients With Lupus Nephritis Submitted to Renal Transplantation. <i>Scientific Reports</i> , <b>2019</b> , 9, 11611	4.9	5
339	Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials. <b>2019</b> , 18, 1500-1506		4
338	Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan. <i>Lupus</i> , <b>2019</b> , 28, 1062-1073	2.6	3
337	Peripheral blood brain-derived neurotrophic factor level and tyrosine kinase B expression on T lymphocytes in systemic lupus erythematosus: Implications for systemic involvement. <i>Cytokine</i> , <b>2019</b> , 123, 154764	4	7
336	Acute respiratory involvement in Colombian patients with systemic lupus erythematosus undergoing chest computed tomography. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 1825-1834	2.3	1

335	Mortality risk prediction in lupus patients complicated with invasive infection in the emergency department: LUPHAS score. <b>2019</b> , 11, 1759720X19885559		3
334	Treatment for refractory lupus nephritis: Rituximab vs triple target therapy. <b>2019</b> , 18, 102406		7
333	Severe Hypogammaglobulinemia Associated with Active Lupus Nephritis Treatment Resulting in Cytomegalovirus Infection. <b>2019</b> , 26, 273		1
332	Urinary Neuropilin-1: A Predictive Biomarker for Renal Outcome in Lupus Nephritis. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	8
331	Ischemic Stroke From Libman-Sacks Endocarditis Not Associated With Antiphospholipid Antibodies: Good Clinical Outcome Without Anticoagulation. <b>2019</b> , 1, 297-300		
330	Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients. <i>Lupus</i> , <b>2019</b> , 28, 1344-1349	2.6	5
329	Infection with Opportunistic Bacteria Triggers Severe Pulmonary Inflammation in Lupus-Prone Mice. <b>2019</b> , 2019, 1701367		1
328	Expression of vitamin D receptor in renal tissue of lupus nephritis and its association with renal injury activity. <i>Lupus</i> , <b>2019</b> , 28, 290-294	2.6	10
327	Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort. <i>Lupus</i> , <b>2019</b> , 28, 295-303	2.6	10
326	Cytomegalovirus infection in Systemic Lupus Erythematosus: report of four cases challenging the management of the disease, and literature review. <i>Lupus</i> , <b>2019</b> , 28, 432-437	2.6	5
325	Oral Manifestations of Systemic Diseases and Their Treatments. <b>2019</b> , 1523-1639		
324	ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. <b>2019</b> , 133, e128-e150		43
323	Peripheral neutrophil CD64 index combined with complement, CRP, WBC count and B cells improves the ability of diagnosing bacterial infection in SLE. <i>Lupus</i> , <b>2019</b> , 28, 304-316	2.6	12
322	Total knee arthroplasty outcomes in lupus: a study using the US National Inpatient Sample. <i>Rheumatology</i> , <b>2019</b> , 58, 2130-2136	3.9	3
321	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. <b>2019</b> , 9, e028697		13
320	Changing hospitalization trends for systemic lupus erythematosus and rheumatoid arthritis in England. <i>Lupus</i> , <b>2019</b> , 28, 906-913	2.6	1
319	IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent. <b>2019</b> , 102, 133-141		12
318	Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort. <i>Lupus</i> , <b>2019</b> , 28, 818-825	2.6	16

317	Systemic Lupus Erythematosus Is Associated With a High Risk of Venous Thromboembolism in Hospitalized Patients Leading to Poor Outcomes and a Higher Cost: Results From Nationwide Inpatient Sample Database 2003-2011. <b>2019</b> , 1, 194-200		4
316	The burden of chronic kidney disease in systemic lupus erythematosus: A nationwide epidemiologic study. <b>2019</b> , 18, 733-737		27
315	Diet and lupus: what do the patients think?. <i>Lupus</i> , <b>2019</b> , 28, 755-763	2.6	7
314	Thrombocytopenia as a Prognostic Marker for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. <b>2019</b> , 357, 461-467		2
313	Characteristics and Histological Types of Lupus Nephritis in a Jordanian Tertiary Medical Center. <b>2019</b> , 2019, 7087461		6
312	Refractory lupus nephritis: When, why and how to treat. <b>2019</b> , 18, 510-518		24
311	Inhibition of IL-17 ameliorates systemic lupus erythematosus in Roquin mice through regulating the balance of TFH cells, GC B cells, Treg and Breg. <i>Scientific Reports</i> , <b>2019</b> , 9, 5227	4.9	24
310	Prevalence and Risk Factors of Reduced Bone Mineral Density in Systemic Lupus Erythematosus Patients: A Meta-Analysis. <b>2019</b> , 2019, 3731648		11
309	Association of toll-like receptor 9 expression with prognosis of systemic lupus erythematosus. <b>2019</b> , 17, 3247-3254		5
308	Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. <b>2019</b> , 14, e0212068		5
307	[Lupus nephritis]. <b>2019</b> , 15, 174-189		2
306	New-onset non-infectious pulmonary manifestations among patients with systemic lupus erythematosus in Sweden. <b>2019</b> , 21, 48		6
305	Effect of pericardial effusion on outcomes in children admitted with systemic lupus erythematosus: a multicenter retrospective cohort study from the United States. <i>Lupus</i> , <b>2019</b> , 28, 389-395	2.6	2
304	Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis. <i>Lupus</i> , <b>2019</b> , 28, 334-346	2.6	19
303	Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus. <b>2019</b> , 14, e0225516		8
302	Cutaneous manifestations of pediatric lupus. <b>2019</b> , 31, 411-420		4
301	Diagnostic potential of ultrasound in systemic lupus erythematosus patients with joint involvement: Relation to anticyclic citrullinated peptide (anti-CCP), disease activity and functional status. <b>2019</b> , 41, 203-207		4
300	Invasive fungal disease in patients with systemic lupus erythematosus from Southern China: a retrospective study. <i>Lupus</i> , <b>2019</b> , 28, 77-85	2.6	13



299	Overview and Clinical Presentation. <b>2019</b> , 389-394		1
298	Lupus and the Nervous System. <b>2019</b> , 434-456		
297	Lupus and Infections. <b>2019</b> , 543-555		2
296	Adjunctive Treatments and Preventive Measures. <b>2019</b> , 702-709		
295	Incidence and risk factors of osteomyelitis in adult and pediatric systemic lupus erythematosus: a nationwide, population-based cohort study. <i>Lupus</i> , <b>2019</b> , 28, 19-26	2.6	5
294	Connective Tissue Disorders in Pregnancy. <b>2019</b> , 37, 121-129		2
293	Knockdown of TRIM27 expression suppresses the dysfunction of mesangial cells in lupus nephritis by FoxO1 pathway. <b>2019</b> , 234, 11555-11566		11
292	Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study. <b>2019</b> , 38, 885-893		2
291	Clinicopathological characteristics and renal outcomes of childhood-onset lupus nephritis with acute kidney injury: A multicenter study. <b>2019</b> , 29, 970-976		2
290	Primary aspergillosis of the kidney in systemic lupus erythematosus and positron emission tomography-computed tomography. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 742-745	2.3	1
289	In systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation. <b>2020</b> , 107, 102355		11
288	The YB-1:Notch-3 axis modulates immune cell responses and organ damage in systemic lupus erythematosus. <b>2020</b> , 97, 289-303		8
287	Manifestations related to alterations in coagulation in systemic lupus erythematosus of juvenile onset. Case report and literature review. <i>Revista Colombiana De Reumatología (English Edition)</i> , <b>2020</b> , 27, 190-201	0.1	
286	ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2020</b> , 59, 2237-2249	3.9	15
285	Previsit Planning Improves Pneumococcal Vaccination Rates in Childhood-Onset SLE. <b>2020</b> , 145,		6
284	Initial renal histology and early response predict outcomes of Brazilian lupus nephritis patients. <i>Lupus</i> , <b>2020</b> , 29, 83-91	2.6	3
283	Prevalence of urogenital mycoplasmas in women with systemic lupus erythematosus (SLE): preliminary study. <b>2020</b> , 39, 717-721		3
282	Evaluating hypercoagulability in new-onset systemic lupus erythematosus patients using thromboelastography. <b>2020</b> , 34, e23157		2

281	Interleukin-17 and lupus: enough to be a target? For which patients?. <i>Lupus</i> , <b>2020</b> , 29, 6-14	2.6	16
280	In-hospital mortality and its predictors in a cohort of SLE from Northern India. <i>Lupus</i> , <b>2020</b> , 29, 1971-1977.	1.6	3
279	Mesenchymal stem cells prevent overwhelming inflammation and reduce infection severity via recruiting CXCR3 regulatory T cells. <b>2020</b> , 9, e1181		8
278	Report of multidrug resistant bloodstream bacterial infections in systemic lupus erythematosus patients in Southern India. <b>2020</b> , 24, 470-472		
277	Reasons for Hospitalization and In-Hospital Mortality in Adult Systemic Lupus Erythematosus. <b>2020</b> , 2, 683-689		4
276	Cytomegalovirus in Indian systemic lupus erythematosus patients: troublemaker or onlooker?. <b>2020</b> , 37, 38		0
275	Reasons for hospitalisation in patients with systemic lupus erythematosus in a university hospital in Buenos Aires. <b>2021</b> , 17, 471-474		
274	Atherosclerosis in Rheumatology: Old and New Insights. <b>2020</b> ,		
273	Systemic Lupus Erythematosus. <b>2020</b> , 172, ITC81-ITC96		84
272	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 572876	8.4	4
271	Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis. <b>2020</b> , 20, 871-884		3
270	Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 586737	8.4	1
269	. <b>2020</b> , 8, 190722-190733		4
268	Multicentre retrospective cohort study assessing the incidence of serious infections in patients with lupus nephritis, compared with non-renal systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7,	4.6	0
267	Lupus nephritis. <b>2020</b> , 6, 7		127
266	Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study. <b>2020</b> , 22, 189		3
265	Prevalence and incidence of systemic lupus erythematosus in Tucum�n, Argentina. <i>Lupus</i> , <b>2020</b> , 29, 1815-1820.	1.6	4
264	Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. <b>2020</b> , 6,		12

263	Identification and characterization of antigen-specific CD4 T cells targeting renally expressed antigens in human lupus nephritis with two independent methods. <i>Scientific Reports</i> , <b>2020</b> , 10, 21312	4.9	2
262	Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 3770-3777	3.9	7
261	Treatment targets in SLE: remission and low disease activity state. <i>Rheumatology</i> , <b>2020</b> , 59, v19-v28	3.9	7
260	Clinical comparisons between previously diagnosed SLE and newly diagnosed SLE by kidney biopsy. <b>2020</b> , 11, 18		0
259	Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease. <b>2020</b> , 21, 450		0
258	Venous Thromboembolic Events in African American Lupus Patients are Less Likely Associated with Antiphospholipid Antibodies Compared to Caucasians. <b>2020</b> ,		0
257	Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. <i>Rheumatology</i> , <b>2020</b> , 59, 3424-3434	3.9	13
256	Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. <i>Rheumatology</i> , <b>2020</b> , 59, 3443-3451	3.9	17
255	Severe pneumonia in Chinese patients with systemic lupus erythematosus. <i>Lupus</i> , <b>2020</b> , 29, 735-742	2.6	7
254	Mortality Among Hospitalized Individuals With Systemic Lupus Erythematosus in the US Between 2006 and 2016. <b>2021</b> , 73, 1444-1450		5
253	A Case of Systemic Lupus Erythematosus/Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome with Dissociated Pathological and Immunological Findings. <b>2020</b> , 2020, 5698708		1
252	In-hospital mortality in patients with systemic lupus erythematosus: a study from Jordan 2002-2017. <b>2020</b> , 40, 711-717		3
251	Response to: 'Glucocorticoid withdrawal in lupus: to do or not to do?' by Acharya. <b>2020</b> ,		
250	Rubrics for mortality: a real-world observational long-term lupus nephritis cohort. <i>Lupus</i> , <b>2020</b> , 29, 1616-1622	1.622	1
249	Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: A systematic review and meta-analysis of observational studies. <b>2020</b> , 50, 1022-1039		15
248	Temporomandibular Disorders and Oral Features in Systemic Lupus Erythematosus Patients: An Observational Study of Symptoms and Signs. <b>2020</b> , 17, 153-160		6
247	Disease activity and damage in hospitalized lupus patients: a Sabah perspective. <i>Lupus</i> , <b>2020</b> , 29, 344-350.	0.6	4
246	Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity. <b>2020</b> , 29, 1745-1756		23

245	Subarachnoid Hemorrhage After Ischemic Stroke Associated with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <b>2020</b> , 136, 248-252		3
244	Septicaemia is associated with increased disease activity and mortality in systemic lupus erythematosus: a retrospective analysis from Taiwan. <i>Lupus</i> , <b>2020</b> , 29, 191-198	2.6	3
243	Prediction of prognosis and renal outcome in lupus nephritis. <i>Lupus Science and Medicine</i> , <b>2020</b> , 7, e000388	3.8	20
242	Infections in early systemic lupus erythematosus pathogenesis. <b>2021</b> , 203-210		
241	Comparison of systemic lupus erythematosus patients and healthy individuals in terms of autobiographical memory, mood, and cognitive emotion regulation. <b>2021</b> , 22, 131-139		0
240	Systemic lupus erythematosus and infections. <b>2021</b> , 451-459		
239	Epidemiology. <b>2021</b> , 21-28		
238	Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time Trends, Health Care Utilization, and In-Hospital Mortality. <b>2021</b> , 73, 617-630		5
237	Bilateral and Multifocal Acquired Cystic Disease-Associated Renal Cell Carcinomas in Patient With End-Stage Renal Disease Caused by Systemic Lupus Erythematosus. <b>2021</b> , 29, 198-204		0
236	Interferon III-related IL28RA variant is associated with rheumatoid arthritis and systemic lupus erythematosus and specific disease sub-phenotypes. <i>International Journal of Rheumatic Diseases</i> , <b>2021</b> , 24, 49-55	2.3	1
235	The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?. <b>2021</b> , 21, 639-647		5
234	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <i>Translational Research</i> , <b>2021</b> , 232, 13-36	11	26
233	Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). <i>Rheumatology</i> , <b>2021</b> , 60, 1793-1803	3.9	8
232	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , <b>2021</b> , 60, 1376-1386	3.9	4
231	Highly sensitive serum cardiac troponin T and cardiovascular events in patients with systemic lupus erythematosus (TROPOPLUS study). <i>Rheumatology</i> , <b>2021</b> , 60, 1210-1215	3.9	2
230	Systemic Lupus Erythematosus. <b>2021</b> , 195-203		
229	Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. <i>Lupus</i> , <b>2021</b> , 30, 702-706	2.6	2
228	Neurorheumatology. <b>2021</b> , 361-372		

227	Recurrent pneumococcal bacteraemia in a patient with systemic lupus erythematosus. <b>2021</b> , 9, 100062		1
226	Fever and Rheumatology. <b>2021</b> , 241-261		
225	Mortality in SLE patients compared with population controls in Finland in years 2000-2015. <i>Rheumatology</i> , <b>2021</b> , 60, 4238-4244	3.9	3
224	Potential therapeutic target genes for systemic lupus erythematosus: a bioinformatics analysis. <b>2021</b> , 12, 2810-2819		5
223	Sepsis Mortality Is high in Patients With Connective Tissue Diseases Admitted to the Intensive Care Unit (ICU). <b>2021</b> , 885066621996257		0
222	The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. <b>2021</b> , 8, 622225		7
221	Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders. <b>2021</b> , 9, 430		
220	Lupus erythematosus: Significance of dermatologic findings. <b>2021</b> , 148, 6-15		0
219	Erythropoietin in Lupus: Unanticipated Immune Modulating Effects of a Kidney Hormone. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 639370	8.4	
218	Atualiza <sup>o</sup> de terap <sup>ut</sup> ica no LES juvenil nefrite. <b>2021</b> , 6-15		
217	The impact of telerheumatology and COVID-19 on outcomes in a tertiary rheumatology service: a retrospective audit. <i>Rheumatology</i> , <b>2021</b> , 60, 3478-3480	3.9	4
216	Infections in systemic autoimmune diseases. <b>2021</b> , 17, 582-587		
215	Increased risk of severe infections and mortality in patients with newly diagnosed systemic lupus erythematosus: a population-based study. <i>Rheumatology</i> , <b>2021</b> , 60, 5300-5309	3.9	2
214	Respiratory Manifestations in Systemic Lupus Erythematosus. <b>2021</b> , 14,		5
213	Implementing the DEcision-Aid for Lupus (IDEAL): study protocol of a multi-site implementation trial with observational, case study design : Implementing the DEcision-Aid for Lupus. <b>2021</b> , 2, 30		0
212	Risk factors for symptomatic Avascular Necrosis (AVN) in a multi-ethnic Systemic Lupus Erythematosus (SLE) cohort. <b>2021</b> , 16, e0248845		5
211	Causes of Mortality Associated with Autoimmune Rheumatic Disease in a Referral Hospital. <i>Reumatologia Cl<sup>in</sup>ica</i> , <b>2021</b> ,	0.9	1
210	Frequency of Systemic Lupus Erythematosus Was Decreasing Among Hospitalized Patients From 2013 to 2017 in a National Database in China. <b>2021</b> , 8, 648727		1

209	Development and internal validation of a clinical prediction model of the risk of nosocomial bacterial infection in patients with systemic lupus erythematosus. <i>Revista Colombiana De Reumatología (English Edition)</i> , <b>2021</b> , 28, 95-103	0.1	
208	Neuropsychiatric involvement in systemic lupus erythematosus: A review. <b>2021</b> , 20, 102780		10
207	Lupus eritematoso sist <sup>^</sup> mico (I). <b>2021</b> , 13, 1739-1750		
206	A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. <b>2021</b> , 6, 1081-1087		4
205	Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
204	Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	4
203	Desarrollo y validaci <sup>^</sup> n interna de un modelo de predicci <sup>^</sup> n cl <sup>^</sup> nica del riesgo de infecci <sup>^</sup> n bacteriana nosocomial en pacientes con lupus eritematoso sist <sup>^</sup> mico. <i>Revista Colombiana De Reumatolog<sup>^</sup>a</i> , <b>2021</b> , 28, 95-103		0.2
202	Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
201	Performing a Safe and Effective Total Hip Arthroplasty on Patients With Inactive or Stably Active Systemic Lupus Erythematosus With Osteonecrosis. <b>2021</b> , 29, 423-432		3
200	Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis. <i>International Immunopharmacology</i> , <b>2021</b> , 94, 107466	5.8	4
199	Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	1
198	Successful treatment of pulmonary aspergillosis due to in a child affected by systemic lupus erythematosus: A case report from Northeastern Iran. <b>2021</b> , 9, e04248		7
197	LONG TERM RENAL SURVIVAL OF PEDIATRIC PATIENTS WITH LUPUS NEPHRITIS. <b>2021</b> ,		1
196	Association of Lupus Nephritis Histopathologic Classification With Venous Thromboembolism-Modification by Age at Biopsy. <b>2021</b> , 6, 1653-1660		1
195	When and How Is It Possible to Stop Therapy in Patients with Lupus Nephritis: A Narrative Review. <b>2021</b> ,		0
194	Infection detection in patients with systemic lupus erythematosus using a hospital administrative database. <i>Revista Colombiana De Reumatolog<sup>^</sup>a</i> , <b>2021</b> ,	0.2	
193	Influenza and pneumococcal vaccination coverage in Latin American patients with systemic lupus erythematosus: a cross-sectional and comparative study. <b>2021</b> , 61, 46		1
192	Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	

191	Absence of renal remission portends poor long-term kidney outcome in lupus nephritis. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	3
190	Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. <b>2021</b> , 19, 137		1
189	A Study of Clinicopathological Correlation in Patients with Lupus Nephritis in a Tertiary Centre in South India. <b>2021</b> , 10, 2789-2794		
188	Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study). <b>2021</b> , 22, 530		
187	Endocrine Manifestations of Systemic Lupus Erythematosus.		
186	Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
185	Autoimmune-mediated renal disease and hypertension. <b>2021</b> , 135, 2165-2196		1
184	Mindfulness-Based Stress Reduction for Systemic Lupus Erythematosus: A Mixed-Methods Pilot Randomized Controlled Trial of an Adapted Protocol. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
183	Contraceptive use and counseling in patients with systemic lupus erythematosus. <b>2021</b> ,		0
182	Causes of mortality associated with autoimmune rheumatic disease in a referral hospital. <b>2021</b> ,		
181	Lupus eritematoso sist <sup>^</sup> mico diagnosticado durante una internaci <sup>^</sup> n: mayor actividad basal de la enfermedad, da <sup>^</sup> o y muerte a corto plazo. <i>Revista Colombiana De Reumatolog<sup>^</sup> a</i> , <b>2021</b> ,	0.2	
180	Reasons for Hospitalisation in Patients with Systemic Lupus Erythematosus in a University Hospital in Buenos Aires. <i>Reumatolog<sup>^</sup> a Cl<sup>^</sup> nica</i> , <b>2020</b> , 17, 471-471	0.9	
179	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <b>2021</b> , 100, S1-S276		91
178	Mast cells in kidney regeneration. <b>2022</b> , 103-126		
177	Hospitalization in patients with systemic lupus erythematosus at Tawam Hospital, United Arab Emirates (UAE): Rates, causes, and factors associated with length of stay. <i>Lupus</i> , <b>2021</b> , 30, 845-851	2.6	1
176	Systemic Lupus Erythematosus. 1-11		3
175	Interstitial Lung Disease in Connective Tissue Diseases Other Than Systemic Sclerosis. <b>2015</b> , 391-418		2
174	Oral Manifestations of Systemic Diseases and their Treatments. <b>2018</b> , 1-117		2

173	Systemic Lupus Erythematosus. <b>2017</b> , 145-163	2
172	Systemic Lupus Erythematosus. <b>2009</b> , 1127-1153	3
171	Time of initial appearance of renal symptoms in the course of systemic lupus erythematosus as a prognostic factor for lupus nephritis. <b>2009</b> , 19, 293-301	6
170	Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. <b>2010</b> , 20, 168-77	6
169	Recent progress in the treatment of lupus nephritis. <b>2012</b> , 22, 803-13	2
168	Epidemiology and classification of systemic lupus erythematosus. <b>2011</b> , 1223-1228.e2	1
167	Systemic Lupus Erythematosus. <b>2010</b> , 1169-1176.e2	1
166	Treat-to-target in systemic lupus erythematosus: Where are we?. <b>2020</b> , 74, 29-34	9
165	Pneumococcal Vaccination Among Lupus Patients: Who Are the Recipients?. <b>2021</b> , 27, e456-e461	0
164	Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases. <b>2020</b> , 16, 200203	5
163	Inflammatory and Lipid-Associated Markers of Cardiovascular Diseases in Children with First Exacerbation of Inflammatory Bowel Disease. <b>2016</b> , 22, 1534-9	7
162	Magnetic Resonance Imaging in Neuropsychiatric Lupus. <b>2015</b> , 4, 162	9
161	Clinicopathological correlations in lupus nephritis; a single center experience. <b>2014</b> , 3, 115-20	13
160	Aberrant activation of the WNT/ $\beta$ -catenin signaling pathway in lupus nephritis. <b>2014</b> , 9, e84852	33
159	High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. <b>2015</b> , 10, e0125618	27
158	Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. <b>2016</b> , 11, e0151696	11
157	The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients. <b>2020</b> , 15, e0240942	3
156	Correlation of echocardiographic findings of pulmonary hypertension with six-minute walk test and plasma pro b-type natriuretic peptide level in systemic lupus erythematosus. <b>2017</b> , 9, 5122-5128	2



155	Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus. <b>2019</b> , 16, 110-118		1
154	Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship. <b>2019</b> , 15, 177-188		12
153	Lupus thrombocytopenia: pathogenesis and therapeutic implications. <b>2017</b> , 28, 20-26		6
152	Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. <b>2017</b> , 28, 4-12		23
151	Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. <b>2019</b> , 30, 7-15		16
150	Genetic Polymorphisms of Interleukin-4 Third Intron Region in the Malaysian Patients with Systemic Lupus Erythematosus. <b>2008</b> , 8, 437-442		3
149	[Lupus-nephritis--diagnosis and treatment]. <b>2010</b> , 130, 1140-4		4
148	Significance of Anti-cyclic Citrullinated Peptide Autoantibodies in Immune-mediated Inflammatory Skin Disorders with and without Arthritis. <i>Indian Journal of Dermatology</i> , <b>2016</b> , 61, 510-4	0.9	3
147	Mortality in systemic lupus erythematosus at a teaching hospital in India: A 5-year retrospective study. <b>2019</b> , 8, 2511-2515		5
146	Risk of cardiovascular disease in inflammatory bowel disease. <b>2014</b> , 5, 359-65		20
145	Intima media thickness measurement as a marker of subclinical atherosclerosis in SLE patient. <b>2014</b> , 158, 404-11		8
144	Fluorine-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography used in diagnosing connective tissue diseases in fever of unknown origin/inflammatory of unknown origin patients. <b>2021</b> , 1		0
143	Simultaneous Systemic Lupus Erythematosus Flare and Disseminated Tuberculosis: Balancing Anti-Mycobacterial and Autoimmune Treatments. <i>Cureus</i> , <b>2021</b> , 13, e18944	1.2	
142	Thrombotic manifestations of VEXAS syndrome. <b>2021</b> , 58, 230-238		2
141	Systemischer Lupus erythematosus. <b>2005</b> , 800-814		
140	Plasmapheresis in Renal Diseases. <b>2008</b> , 125-139		
139	Neurovascular Consequences of Systemic Disease I Collagen Vascular Disease. <b>2009</b> , 203-220		
138	Systemic Lupus Erythematosus.		1

- 137 Epidemiology. **2010**, 3-4
- 136 Kollagenosen. **2010**, 99-127
- 135 Connective Tissue Diseases. **2011**, 155-181
- 134 Antiphospholipid Syndrome in the Older Population. **2011**, 231-239
- 133 Task Force Report on Brain Involvement in Antiphospholipid Syndrome. **2012**, 159-166
- 132 Kollagenosen. **2012**, 103-131
- 131 Vasculitis in Systemic Lupus Erythematosus. 419-432
- 130 Quel est le risque infectieux viral d'un lupique ?. **2013**, 173-182
- 129 Atteintes pleuro-pulmonaires associ es au lupus  lyth mateux. **2013**, 273-281
- 128 Que faire en pr sence d'anticorps antiphospholipides chez un malade lupique sans pass  thrombotique ni obst trical ?. **2013**, 99-102
- 127 A Frayed Knot. 69-76
- 126 Contraception for Women with Rheumatologic Disease. **2014**, 307-320
- 125 Splenic Infarction as the Initial Manifestation of Antiphospholipid Syndrome in a Systemic Lupus Erythematosus Patient. **2014**, 86, 651 o
- 124 Renal Involvement in Children with Systemic Lupus Erythematosus. **2015**, 1-45
- 123 Magnetic Resonance Imaging in Neuropsychiatric Lupus. **2015**, 4, 162 12
- 122 Renal Involvement in Children with Systemic Lupus Erythematosus. **2016**, 1449-1488
- 121 Epidemiology. **2016**, 15-21
- 120 Lupus Nephritis. **2016**, 759-780

- 119 Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibodies and C-Reactive Protein in Common Autoimmune Skin Diseases with and without Arthritis. **2017**, 11, BC06-BC08 1
- 118 Kollagenosen. **2017**, 75-96
- 117 The importance of M694V mutation in systemic lupus erythematosus; implications for its role in neutrophil extracellular traps associated renal involvement. **2017**, 6, 374-379
- 116 Disease manifestations. **2018**, 39-70
- 115 Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy. *Cureus*, **2017**, 9, e1907 1.2 1
- 114 Prognostic Aspects of Lupus Nephritis at Aristide Le Dantec University Hospital in Dakar. **2018**, 08, 124-132
- 113 Lupus in fabula: Hypertension of a younger man and systemic lupus erythematosus. **2018**, 43, 26-30
- 112 Systemic Lupus Erythematosus. **2018**, 285-304
- 111 The Association Between Erythrocyte Sedimentation Rate, C3, C4, Anti-dsDNA Levels, and Renal Disease Activity, Based on BILAG Index in Females With Lupus Nephritis. **2018**, 10,
- 110 Daño de órgano en una cohorte de pacientes colombianos con lupus eritematoso sistémico: caracterización y factores asociados. *Revista Colombiana De Reumatología*, **2018**, 25, 85-91 0.2 1
- 109 Inhibition of miR-22-3p reduces kidney disease associated with systemic lupus erythematosus.
- 108 Systemic lupus erythematosus presenting as stevens johnson syndrome in a thirty years old female: a case report. **2019**, 6, 20-21
- 107 Evaluation of clinical and laboratory findings of 147 patients with systemic lupus erythematosus: The relationship between anti-CCP and arthritis.
- 106 Pericarditis in Lupus. *Cureus*, **2019**, 11, e4166 1.2 10
- 105 Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity.
- 104 Pulmonary involvement in systemic lupus erythematosus, Sjögren syndrome and mixed connective tissue disease. **2019**, 106-123 1
- 103 Neurovascular Consequences of Systemic Disease: Lupus and Primary Hyperparathyroidism. **2020**, 303-335
- 102 Hipercoagulabilidad y autoinmunidad. **2020**, 35, 98-103

101	Factors Associated with Renal Outcomes in an Inception Cohort of Biopsy-proven Lupus Nephritis Patients. <i>Journal of Clinical Rheumatology and Immunology</i> , <b>2020</b> , 20, 9-20	0	
100	Ciprofloxacin-Induced Reaction Imitating a Lupus Flare: A Case Report. <i>Cureus</i> , <b>2020</b> , 12, e8327	1.2	1
99	Efficacy and Safety of Vaccinations in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology and Immunology</i> , <b>2020</b> , 20, 35-41	0	
98	Manifestaciones relacionadas con alteraciones en la coagulaci <sup>3</sup> n en lupus eritematoso sist <sup>3</sup> mico de inicio juvenil. Reporte de casos y revisi <sup>3</sup> n de la literatura. <i>Revista Colombiana De Reumatolog<sup>3</sup>a</i> , <b>2020</b> , 27, 190-201	0.2	
97	Infections in systemic autoimmune diseases. <i>Reumatolog<sup>3</sup>a Cl<sup>3</sup>nica</i> , <b>2020</b> , 17, 582-582	0.9	2
96	Autoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis. <i>Emergency Medicine Clinics of North America</i> , <b>2022</b> , 40, 179-191	1.9	1
95	Serum procalcitonin and C-reactive protein levels as diagnostic markers for distinguishing bacterial infections from lupus flares in systemic lupus erythematosus: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , <b>2021</b> , 101, 108304	5.8	1
94	Clinicopathological and Immunological Profile of Patients with Cutaneous Manifestations and their Relationship with Organ Involvement in Systemic Lupus Erythematosus Attending a Tertiary Care Center of Eastern India. <i>Indian Journal of Dermatology</i> , <b>2020</b> , 65, 22-28	0.9	0
93	Isolevuglandins promote autoimmunity and hypertension in systemic lupus erythematosus.		
92	Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry. <i>American Journal of Kidney Diseases</i> , <b>2021</b> ,	7.4	0
91	Risk assessment and prognostic analysis of patients with splenic infarction in emergency department: a multicenter retrospective study. <i>Scientific Reports</i> , <b>2021</b> , 11, 21423	4.9	1
90	Neuro-Psychiatric Systemic Lupus Erythematosus. <b>2005</b> , 311-329		
89	Nontuberculous mycobacteria infections in patients receiving immunosuppressive agents. 238-253		
88	Contraception for Women with Rheumatologic Disease. <b>2014</b> , 307-320		0
87	The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I. <i>Sovremennaya Revmatologiya</i> , <b>2020</b> , 14, 7-15	0.7	
86	Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. <i>Ethnicity and Disease</i> , <b>2008</b> , 18, S2-205-10	1.8	6
85	Systemic lupus erythematosus. <i>Clinical Evidence</i> , <b>2009</b> , 2009,		0
84	Manifestations of systemic lupus erythematosus. <i>M<sup>3</sup>dica</i> , <b>2011</b> , 6, 330-6		50

83	Autoimmune diseases and venous thromboembolism: a review of the literature. <i>American Journal of Cardiovascular Disease</i> , <b>2012</b> , 2, 171-83	0.9	81
82	Systemic lupus erythematosus: lupus nephritis. <i>Clinical Evidence</i> , <b>2015</b> , 2015,		1
81	Metabolic syndrome in lupus patients in northeast of Iran, and their lifestyle habits. <i>Caspian Journal of Internal Medicine</i> , <b>2016</b> , 7, 195-200	1	3
80	Clinical and serological features of patients with systemic lupus erythematosus in the eastern province of Saudi Arabia: A prospective cohort study. <b>2021</b> , 1, 7		
79	Renal function deterioration is an independent mortality determinant in Koreans diagnosed with lupus nephritis. <i>Lupus</i> , <b>2021</b> , 30, 1896-1905	2.6	1
78	The Role of NLRP3 Inflammasome in Lupus Nephritis. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	5
77	Multimodality Cardiac Imaging in Patients with Systemic Lupus Erythematosus. <i>Current Problems in Cardiology</i> , <b>2021</b> , 101048	17.1	1
76	Systemischer Lupus erythematosus. <b>2015</b> , 1-13		
75	Predicting Kidney Survival in Lupus Nephritis by Adding Clinical Data to Pathologic Features.. <i>Kidney360</i> , <b>2022</b> , 3, 5-7	1.8	0
74	Central nervous system infections in patients with systemic lupus erythematosus: a systematic review and meta-analysis.. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9,	4.6	1
73	Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study.. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9,	4.6	0
72	Mécanismes physiopathologiques du lupus systémique. <i>Bulletin De L'Académie Nationale De Médecine</i> , <b>2022</b> , 206, 7-16	0.1	0
71	Descriptive study of pneumococcal vaccination in cases of inflammatory disease: analysis of practices.. <i>Infectious Diseases Now</i> , <b>2022</b> ,		
70	Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2022</b> , 70, 8	4	0
69	Clinicopathological study of males with lupus nephritis: Pathologist's experience at a tertiary-care center. <i>Indian Journal of Nephrology</i> , <b>2022</b> ,	0.8	
68	Silica-associated systemic lupus erythematosus with lupus nephritis and lupus pneumonitis: A case report and a systematic review of the literature.. <i>Medicine (United States)</i> , <b>2022</b> , 101, e28872	1.8	
67	Clonal hematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study).. <i>Rheumatology</i> , <b>2022</b> ,	3.9	0
66	Association of Osteopontin gene single nucleotide polymorphism with lupus nephritis.. <i>International Journal of Rheumatic Diseases</i> , <b>2022</b> ,	2.3	0

65	Twenty-year trends in all-cause mortality of patients with systemic lupus erythematosus in Mexico: Results from a nationwide health registry.. <i>Lupus</i> , <b>2022</b> , 9612033221078228	2.6	1
64	Systemic lupus erythematosus diagnosed during hospitalization: Greater baseline disease activity, short-term damage, and death. <i>Revista Colombiana De Reumatología (English Edition)</i> , <b>2022</b> ,	0.1	
63	Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.. <i>Translational Research</i> , <b>2022</b> ,	11	0
62	T Helper 2-Associated Immunity in the Pathogenesis of Systemic Lupus Erythematosus.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 866549	8.4	0
61	Interleukin-38 in Health and Disease.. <i>Cytokine</i> , <b>2022</b> , 152, 155824	4	2
60	Trends in Hospital Admissions and Death Causes in Patients with Systemic Lupus Erythematosus: Spanish National Registry.. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
59	Risk factors for thrombotic events in Korean patients with systemic lupus erythematosus. <i>Scientific Reports</i> , <b>2021</b> , 11, 23529	4.9	1
58	A prescription for exercise in systemic lupus erythematosus.. <i>Lupus</i> , <b>2021</b> , 9612033211061060	2.6	
57	Performance of the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus in a multiethnic Malaysian cohort.. <i>International Journal of Rheumatic Diseases</i> , <b>2021</b> ,	2.3	0
56	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	5
55	Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study.. <i>Lupus</i> , <b>2022</b> , 9612033221095149	2.6	1
54	Anti-phospholipid antibody syndrome. 263-274		2
53	DataSheet_1.pdf. <b>2020</b> ,		
52	Table_1.pdf. <b>2020</b> ,		
51	OUP accepted manuscript. <i>journal of applied laboratory medicine</i> , <i>The</i> ,	2	1
50	Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study. <i>Lupus Science and Medicine</i> , <b>2022</b> , 9, e000677	4.6	
49	Th17 and Th1 cells in systemic lupus erythematosus with focus on lupus nephritis. <i>Immunologic Research</i> ,	4.3	1
48	Kidney biopsy in lupus nephritis after achieving clinical renal remission: paving the way for renal outcome assessment. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	

47	Gain-of-function TLR7 and loss-of-function A20 gene variants identify a novel pathway for Mendelian lupus and lupus nephritis. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	
46	Chronic Immune Platelet Activation Is Followed by Platelet Refractoriness and Impaired Contractility. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 7336	6.3	2
45	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 096120332211156	2.6	0
44	Gut Barrier Damage and Gut Translocation of Pathogen Molecules in Lupus, an Impact of Innate Immunity (Macrophages and Neutrophils) in Autoimmune Disease. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 8223	6.3	2
43	Identification of biomarkers related to neutrophils and two molecular subtypes of systemic lupus erythematosus. <b>2022</b> , 15,		1
42	Infection detection in patients with systemic lupus erythematosus using a hospital administrative database. <b>2022</b> , 29, 171-176		
41	Good Long-Term Prognosis of Lupus Nephritis in the High-Income Afro-Caribbean Population of Martinique with Free Access to Healthcare. <b>2022</b> , 11, 4860		0
40	Infection profile and risk factors for mortality in patients with end-stage renal disease attributable to systemic lupus erythematosus: a two-center integrated study. <b>2022</b> , 50, 030006052211187		
39	Long-term Survival Analysis of Free Flap Reconstruction in Patients with Collagen Vascular Disorders. <b>2022</b> ,		
38	Persistent isolated C3 hypocomplementemia as a strong predictor of end-stage kidney disease in lupus nephritis. <b>2022</b> ,		1
37	Predicting the effect of sirolimus on disease activity in patients with systemic lupus erythematosus using machine learning.		0
36	Egyptian evidence-based consensus on clinical practice recommendations for the management of lupus nephritis. <b>2022</b> , 49,		0
35	CŪr et mˆ decine interneˆ : lupus systˆ mique et syndrome des antiphospholipides. <b>2022</b> ,		0
34	A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. <b>2022</b> , 39, 4910-4960		3
33	Systemic Lupus Erythematosus and ANCA-Associated Vasculitis Overlap Syndrome: A Case Report. <b>2022</b> , 100544		0
32	Heterogeneity of Stroke in Patients with Systemic Lupus Erythematosus. <b>2022</b> , 61, 3045-3052		1
31	Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. <b>2022</b> , 11, 6016		2
30	Accelerated Atherosclerosis in SLE: Mechanisms, Consequences, and Future Directions.		0

- 29 Autoimmune Pericarditis: Multimodality Imaging. 1
- 28 Primary Healthcare Practitioners' Knowledge, Attitude, and Practice Toward Systemic Lupus Erythematosus in the Qassim Region, Saudi Arabia. **2022**, ○
- 27 Diagnostic test accuracy of novel biomarkers for lupus nephritis: An overview of systematic reviews. **2022**, 17, e0275016 ○
- 26 Impact of severe infections in SLE: an observational study from the Spanish national registry. **2022**, 9, e000711 ○
- 25 Pattern and clinical phenotype of systemic lupus erythematosus among male patients: Hospital-based study. **2022**, 2, ○
- 24 Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentre real-world study. **2022**, 9, e000779 ○
- 23 Venous Thromboembolism in the Inflammatory Rheumatic Diseases. **2023**, 49, 97-127 ○
- 22 Clinical Overview of Inflammatory Dermatologic Conditions. **2022**, 341-344 ○
- 21 Baseline Proteinuria and Serum Creatinine Concentration as Clinical Predictors of Complete Renal Response in Patients with Lupus Nephritis: A Single-Center Experience. **2022**, 19, 15909 ○
- 20 Validity of immunoglobulin-binding protein 1 as a biomarker for lupus nephritis. 096120332211412 ○
- 19 Analysis of Cardiovascular Complications During Delivery Admissions Among Patients With Systemic Lupus Erythematosus, 2004-2019. **2022**, 5, e2243388 ○
- 18 A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. 13, ○
- 17 Mesangial cell: A hub in lupus nephritis. 13, ○
- 16 Stroke and Systemic Lupus Erythematosus: A Review. 100-107 ○
- 15 Sex-Specific Outcomes of Acute Stroke in Patients with Systemic Lupus Erythematosus: A National Inpatient Sample Study. **2023**, 12, 462 ○
- 14 Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. **2023**, 24, 1331 ○
- 13 Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren's syndrome and systemic sclerosis. **2022**, 9, e000732 ○
- 12 Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil. 096120332311535 ○



- 11 Incorporating knowledge of disease-defining hub genes and regulatory network into a machine learning-based model for predicting treatment response in lupus nephritis after the first renal flare. **2023**, 21, ○
- 10 Severe infections in patients with systemic lupus erythematosus from Tunisia: Prevalence and risk factors. 096120332311663 ○
- 9 Tuberculosis remains a leading contributor to morbidity due to serious infections in Indian patients of SLE. ○
- 8 Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus. **2023**, 5, e151-e165 ○
- 7 Tuberculosis remains a major burden in systemic lupus erythematosus patients in Durban, South Africa. 10, ○
- 6 Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Medium-to-High-Dose Glucocorticoids. 096120332311607 ○
- 5 Blood levels of brain-derived neurotrophic factor (BDNF) in systemic lupus erythematosus (SLE): a systematic review and meta-analysis. **2023**, 63, ○
- 4 Lupus Nephritis. **2023**, 737-763 ○
- 3 Lung Disease in Systemic Lupus Erythematosus, Myositis, Sjögren Disease, and Mixed Connective Tissue Disease. **2023**, 223-239 ○
- 2 Combination of anti-C1qA08 and anti-mCRP a.a.35-47 antibodies is associated with renal prognosis of patients with lupus nephritis. 14, ○
- 1 Cardiovascular manifestations in idiopathic inflammatory myopathies. ○